Role and Contribution of A2 Adenosine Receptors in the Regulation of Coronary Flow by Sharifi Sanjani, Maryam
Graduate Theses, Dissertations, and Problem Reports 
2011 
Role and Contribution of A2 Adenosine Receptors in the 
Regulation of Coronary Flow 
Maryam Sharifi Sanjani 
West Virginia University 
Follow this and additional works at: https://researchrepository.wvu.edu/etd 
Recommended Citation 
Sharifi Sanjani, Maryam, "Role and Contribution of A2 Adenosine Receptors in the Regulation of Coronary 
Flow" (2011). Graduate Theses, Dissertations, and Problem Reports. 4788. 
https://researchrepository.wvu.edu/etd/4788 
This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research 
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is 
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain 
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license 
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, 
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. 
For more information, please contact researchrepository@mail.wvu.edu. 
Role and Contribution of A2 Adenosine Receptors in the Regulation of Coronary Flow 
 
Maryam Sharifi Sanjani 
 
 
Dissertation submitted to the School of Pharmacy at West Virginia University in partial 
fulfillment of the requirements for the degree of 
 
Doctor of Philosophy 
in 
Pharmaceutical and Pharmacological Sciences 
 
 
S. Jamal Mustafa, Ph. D., Chair 
Matthew Boegehold, Ph. D. 
Robert Brock, Ph. D. 
Jeffrey Fedan, Ph. D. 
Jason Huber, Ph. D. 
 
Department of Pharmaceutical and Pharmacological Sciences 
 
 
Morgantown, West Virginia 
2011 
 










Role of A2 Adenosine Receptors in the Regulation of Coronary Flow 
 
Maryam Sharifi Sanjani 
 
 
One out of three individuals suffer from one form of cardiovascular disease, out of which, 
about 6,000,000 individuals suffer from coronary heart disease. Adenosine has long been known 
to play a role in coronary flow (CF) regulation; however, the individual role of A2A and A2B 
adenosine receptors (AR) and their contribution is yet to be fully elucidated. The purpose of this 
study was to characterize the pharmacology of both A2 ARs in coronary arteries (CAs), in 
addition, to identifying their role in reactive hyperemia, and their signaling mechanisms. We 
hypothesized that A2 ARs mediate an increase in CF, in addition, to being involved in metabolic 
control of CF. Therefore, in this study, we investigated CF changes due to exogenous activation 
of A2A and A2B ARs, in addition, to their endogenous activation during coronary reactive 
hyperemia, when metabolic factors, such as adenosine, play a pivotal role. We used the well 
established Langendorff isolated heart system as well as selective and non-selective AR agonists 
and antagonists, and A2A and A2B AR single and double knockout mice. We found that activation 
of both A2A and A2B ARs induces an increase in CF, albeit with different pharmacological 
profile. Further, in A2BKO mice, A2AARs are up-regulated in order to compensate for deletion of 
A2BARs. These findings may suggest that both A2ARs are capable of increasing the CF in 
conditions when a sufficient level of adenosine is available. However, we also found that only 
A2AARs contribute to CF changes in coronary reactive hyperemia, which may suggest that 
A2BARs may be activated in more severe conditions such as longer ischemic conditions, where 
adenosine levels are significantly augmented. We next investigated signaling pathways involved 
in A2AR-mediated effects. We found that non-mitochondrial KATP channels are a major end 
effectors in A2AR-induced increase in CF. What is more interesting is that we illustrated that 
H2O2 mediates adenosine’s effect on CF and that is coupled to adenosine-mediated effect on 
KATP channels. From these data, it can be concluded that A2A and A2B ARs may regulate CF in 
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Adenosine, produced by all cells, is an endogenous purine nucleoside with 
various physiological effects induced through its four subtypes of receptors A1, A2A, A2B, 
and A3. Figure 1.1 illustrates the chemical structure of adenosine. Adenosine induces its 
effects All adenosine receptors (AR) are G protein coupled receptors (GPCR) and have 
their own pharmacological profile and affinity for adenosine, tissue distribution, and 
effector coupling. Therefore, effects mediated through adenosine depend on the AR 
subtype activated.  
Generation of adenosine and its metabolism 
In physiological conditions, adenosine is produced from intracellular conversion 
of S-adenosyl-L methionine (SAM) to S-adenosyl-L-homocysteine (SAH) which then is 
converted to adenosine and homocysteine by SAH-hydrolase (30, 48) (Figure 1.2). 
Cytosolic adenosine can become phosphorylated via adenosine kinase to AMP in 
addition to getting converted to inosine by adenosine deaminse (ADA), especially at high 
levels of adenosine. Intracellular adenosine is transported down the concentration 
gradient into the extracellular space via equillibrative membrane transporters. Adenosine 
can also be produced extracellular through successive dephosphorylation of ATP to ADP 
and then ADP to AMP, which then goes under hydrolysis via membrane-bound ecto-5′-
nucleotidases CD39 and CD73 in order to form adenosine. By the action of ADA, 
extracellularly produced adenosine can also be further converted to inosine which is 
finally broken down to uric acid that is excreted in urine. However, adenosine can also 
get re-converted to AMP via the enzyme adenosine kinase (AK). Nevertheless, 
extracellularly produced adenosine can also be transported into the cell via concentration- 
and/or sodium-dependent transporters (Figure 1.2). In addition to being metabolized, 
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Figure 1.2 Production of adenosine under physiological conditions. Scheme adapted 




Coronary flow regulation  
 Coronary arteries (CAs) play a pivotal role in determining the oxygen and nutrient 
supply of the myocardium by regulating the coronary flow (CF). Myocardial perfusion is 
regulated by several factors released from endothelial cells, smooth muscle cells, and 
cardiomyocytes that affect the coronary vascular tone. It is well known that physical 
forces induce coronary responses known as myogenic and flow-induced (shear stress) 
vascular control that determine the vascular basal tone and CF (Figure 1.3). Also, 
metabolic factors such as adenosine have been shown to mediate CA responses during 
metabolic stimulation (active hyperemia), autoregulation, and/or reactive hyperemia 
(Figure 1.3). Moreover, sympathoneural factors such as the effect of β adrenoceptors 
(ADR) are reported to affect the coronary tone through endothelium-dependent and –
independent manners (Figure 1.3).  
 Pressure-induced myogenic constriction importantly contributes to autoregulation 
of local blood flow, which also acts as a protective measure from sudden increases in 
arterial pressure (88). Given that this constriction allows resistance arteries, such as 
coronary arterioles, to constrict or dilate in response to vasoactive mediators and changes 
in intraluminal pressure, it counts as an essential component of basal microvascular tone 
where vascular resistance is tightly regulated (19). The myogenic response occurs 
independently of the endothelium and perivascular nerves and is, therefore, an inherent 
property of vascular smooth muscle cells (85, 98). Smooth muscle cells have stretch-
activated cation channels that, when activated, induce an inward current leading to cell 
membrane depolarization and constriction (22-23, 160). Previous studies have shown that 
increased intraluminal pressure leads to depolarization of smooth muscle cells and the 
opening of Ca
2+
 channels, such as Ca
2+





 leading to the contraction and the increase in myogenic tone 
(53-54, 108). Several endogenous mediators, such as cytochrome P450 metabolites, have 
been suggested to be involved in myogenic tone control via activation of BKCa channels 
(158). The CA myogenic tone is also proposed to be regulated by several molecular 
signaling pathways, such as, PKC pathway (29, 83, 99) and MAPK/ERK1/2 pathway 
(76-78). Moreover, the myogenic constriction in CA is suggested to antagonize EDHF-
mediated dilation; it was reported that activation of BKCa channels reduces myogenic 
constriction and profoundly increases EDHF-mediated dilation in CA (54).   
 An increase in wall shear stress results in the release of various factors from the 
endothelium that subsequently act on smooth muscle cells in order to induce vasodilation 
(86, 122, 150, 165). This illustrates the release of endothelium-derived factors that may 
limit myogenic constriction. Endothelium-derived nitric oxide (NO), suggested as 
endothelium-derived relaxing factor (EDRF), was proposed to regulate the coronary 
reactive hyperemia responses (80, 150, 165). However, other non-NO and non-prostanoid 
endothelium-derived substances, referred to as endothelium-derived hyperpolarizing 
factors (EDHFs), were found to play an important role in the regulation of CA vascular 
tone. Epoxyeicosatrienoic acids (EETs) (46, 128), H2O2 (96, 101, 163), and K
+
 (6) are a 
few suggested EDHFs in coronary arteries to highlight. Liu et al. showed that 
endothelial-derived H2O2 was critical in human CA dilation to shear stress (90, 101). The 
same group also suggested that mitochondria are the source of the H2O2 generation that 
plays a role in flow-induced human CA dilation (90). Miura et al. reported that shear 
stress induces endothelium-dependent vasodilation through CYP450 metabolites leading 
to hyperpolarization of smooth muscle cells through BKCa channels in human coronary 
arterioles (103). It should be highlighted that human CAs in these studies are dissected 
7 
 
from patients with cardiovascular disease, which may lead to different physiological 
responses than true controls, the tissues from healthy individuals. Nevertheless, previous 
studies have shown that endothelial production of NO can be triggered by mechanical 
shear forces or CF-induced pulsatile strain (154-155). It was demonstrated that NO 
contributes to the coronary responses in reactive hyperemia (167)and that adenosine is 
involved in CA flow-induced dilation and enhanced coronary response to pulsatile 
perfusion(87, 117, 169), which suggests the existence of a cooperative interaction 
between adenosine and the local flow regulation mechanisms.  
It is well established that CF is regulated by the metabolic state of the heart (44) 
(Figure 1.3). Berne’s adenosine hypothesis suggests that increases in myocardial oxygen 
consumption decreases myocardial oxygen tension (pO2) which leads to the release of 
adenosine from cardiomyocytes (8, 43, 159). Furthermore, a role for H2O2 in metabolic 
CA vasodilation has been established (72, 116, 164). Chilian et al. suggested that H2O2 
production increases in proportion to cardiac metabolism in order to couple the coronary 
blood flow to myocardial oxygen tension (131). On the other hand, increasing evidence 
has shown the involvement of KATP channels in metabolic CF adjustment through 
different approaches such as pacing-induced tachycardia (73), pharmacological metabolic 
stimulation (110), and exercise (36). Further, coronary arteriolar smooth muscle KATP 
channels (42, 124-125) and BKCa channels were reported to contribute to the basal CF 
regulation (53). There is evidence that during exercise, coronary NO production is 
increased in the heart (136), likely due to an increase in endothelial shear stress 
secondary to the increased CF rate (9, 149). Nevertheless, Chilian et al. demonstrated that 
CA vasoconstriction induced by inhibition of NO was counterbalanced by coronary 
vasodilation, indicating that many compensatory vasomotor adjustments occur in order to 
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maintain the CF (71). And finally, the knowledge that prostaglandins may also act as 
local chemical mediators to control coronary perfusion to adapt to the metabolic demands 




Figure 1.3 Several reported pathways for metabolic vasodilation of coronary 





It has been known that neurotransmitters released from nerve endings are known 
to affect the coronary vascular tone. Sympathetic stimulation-mediated coronary 
vasoconstriction is capable of competing with local metabolic control to lower coronary 
venous oxygen tension (44). The autonomic effects on CF regulation have been studied at 
rest and during exercise through different approaches such as after surgical or chemical 
denervation of the heart or in the presence of selective autonomic receptor antagonists. It 
was reported that cardiac neural ablation did not impair the ability to maintain the 
exercise level, although the initial hemodynamic adjustment to exercise was delayed (52). 
It is established that blockade of α2-adrenoceptors (ADR) can affect the CF through three 
mechanisms: a) blockade of prejunctional αADR which interrupts the negative-feedback 
control of norepinephrine release leading to an increase in norepinephrine levels and 
induction of cardiac ßADR stimulation and an increase in CF (60, 62); b) αADR 
blockade can increase CF by interrupting vasoconstriction mediated by postjunctional α1 
and  α2ADRs located on CA smooth muscle cells; and c) α2ADR on CA endothelial cells 
can stimulate release of nitric oxide (NO), which can oppose the αADR-mediated 
vasoconstriction (20, 65). On the other hand, it was reported that norepinephrine brings 
about human coronary vasodilation through ß2ADR (139) that involves NO and KATP 
channels (100). Previous studies suggested that ß2ADR-mediated CF regulation is 
minimal under resting conditions in dogs (5, 61) while, βADRactivation was shown to 
contribute to coronary vasodilation during exercise in a feed-forward manner (104-105, 
153). β2ADR activation during exercise causes a significant degree of CA dilatation 
independent of myocardial effects of β1ADR stimulation (31, 94). Overall, the consensus 
is that βADR blockade causes a greater reduction in CF compared to myocardial oxygen 
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consumption, resulting in increased oxygen extraction by the heart which demonstrates a 
direct feed-forward for βADR CA vasodilatory effect.  
In this thesis, based on previous studies on adenosine and the existence of broad 
factors involved in the regulation of CF, we elaborate on the role of adenosine, KATP 
channels, and H2O2 in addition to a brief look at β adrenoceptors, as a sympathoneural 
factor, in light of adenosine as the main focus.  
12 
 
Figure 1.4 Previously reported major signal transduction pathways in the regulation 







Role of adenosine in coronary flow regulation  
  The heart has a small anaerobic metabolic capacity and, therefore, is essentially 
dependent on CF in order to provide the heart with oxygen on a beat to beat basis. Some 
also say that heart function is comprised of continuous sequential episodes of transient 
increase in CF, called reactive hyperemia (RH), with the decreased flow occurring during 
the systole and the RH response occurring during the diastole. Additionally, during 
conditions such as coronary vasospasm or even exercise the myocardium is also 
responsive to acute periods of decreased CF by means of RH. Nevertheless, as 
mentioned, the increase in CF during more aggressive conditions such as exercise or 
angina plays a crucial role in providing the heart with necessary oxygen. However, it is 
interesting to note that the myocardium is reported to only extract about 75% of the 
delivered oxygen at rest and that the seemingly high level of repayment during episodes 
of RH only provides oxygen repayment ratios of between 26-82% (129), which suffice to 
say that myocardium has a small oxygen extraction reserve and that the contribution of 
any vasodilatory factor plays a crucial role for the regulation of CF and the efficient 
oxygen supply and, hence, cardiac function. Needless to say that although the myocardial 
oxygen supply (in the form of blood flow or oxygen extraction) is small, the myocardial 
oxygen consumption can increase up to five fold when needed (43).  
In 1963, Berne et al. proposed the adenosine hypothesis (7). The idea was that the 
myocardial oxygen supply over oxygen consumption ratio is reflected in the intracellular 
myocardial oxygen tension (pO2). For example, if myocardial oxygen supply over 
consumption ratio decreases (as during exercise), the myocardium encounters a fall in 
pO2 which leads to the breakdown of adenine nucleotides (ATP, ADP, AMP) and, hence, 
generation of adenosine. The produced adenosine then diffuses out of the cell to act on its 
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receptors on coronary arteriolar smooth muscle cells (through an endothelium-dependent 
and –independent manner) in order to cause vasodilation. This increase in CF delivers 
more oxygen to the myocardium and, thus, returns myocardial pO2 back toward the 
normal range (Figure 1.5). The adenosine hypothesis is also a transmitter hypothesis 
which suggests that adenosine transmits information regarding the status of one cell type 
such as cardiomyocyte to another cell type such as arteriolar smooth muscle by diffusing 
across the interstitial space (43, 48). Therefore, Berne’s adenosine hypothesis suggests 
that adenosine coordinates the myocardial oxygen consumption to CF (Figure 1.5). The 
role of each AR subtype in the regulation of CF has been extensively studied. 
Adenosine receptors classification and characteristics 
Adenosine receptors were initially classified into A1 and A2 subtypes based on 
their potency for ligands and antagonism by methylxanthines (91). Subsequently 
subclassification of A2 into A2A and A2B subtypes was pharmacologically based upon the 
high affinity A2A and low affinity A2B binding sites in rat brain (24). All ARs are seven 
transmembrane GPCR with approximately 21–28 amino acids in each transmembrane 
region. The A2AAR is 409 and 410 amino acids long in human and mouse, respectively.  
A2AAR is the largest of all ARs due to its extended C-terminus of no known function 
(121). Overall, there is relatively low level of amino acid homology between different 
ARs in a single species in addition to the same AR between species which may contribute 
to the different ARs-mediated effects observed in different species. 
The N-terminus of ARs are extracellular and it was shown that all ARs other than 
A2AAR have a palmitoylation site near the C-terminus (1). Furthermore, all ARs are 
glycosylated on their 2
nd
 extracellular loop (121) and although the 3
rd
 intracellular loop is 
involved in both A1 and A2AAR G protein coupling, the C-terminus is only involved in 
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A1AR G protein coupling (151). It was also reported that the A2AAR phosphorylation of 
intracellular loop is involved in this AR desensitization (118). Currently, all four ARs are 
cloned and their expressions in various tissues have been extensively studied. 
The A2AAR gene has been localized to chromosome 22q11.23 (27, 92) and 
chromosome 10 in human and mouse, respectively (162). However, the A2BAR gene has 
been localized to chromosome 17p12-11.2 (69) chromosome 11 in human and mouse, 
respectively (162). A2AAR was the first AR genetically modified in a murine model (89). 
The A2AAR knockout (KO) mice were developed in three different genetic backgrounds 
of CD1, congenic C57B L/6, and pure 129-Steel (17-18, 89) while A2BAR has been 
recently developed only in C57BL/6 background. A2AKO animals demonstrated several 
central nervous system disturbances such as decreased exploratory activity, increased 
aggressiveness and hypoalgesia (89). Furthermore, A2AKO mice with CD1 genetic 
background were demonstrated to have increased blood pressure, heart rate, and platelet 
aggregation (89) while an A2AKO mice on either a mixed 129Steel-C57BL/6 or congenic 
C57BL/6 genetic background did not show any change in blood pressure(17, 26). While 
there are relatively a large number of studies on A2AKO, there are not many studies using 
A2BKO mice and, therefore, a better understanding of its functional effects or 
compensatory mechanisms due to its genetic modification still remains to be fully 
elucidated. 
A2ARs: The presence of both A2A and A2BARs on coronary endothelial and 
smooth muscle cells and the pivotal vasoregulatory role of adenosine in human CA is 
well established (37-38, 113, 130, 133). The involvement of A2AAR in the regulation of 
CF in various other species has been also broadly reported (11, 37-38, 74, 106, 130, 133, 
137, 142, 145, 167). Previous studies further suggest that metabolic vasodilatory factors 
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such as adenosine are the primary mediators responsible for the CF regulation during RH 
(21, 63, 114-115).  In vivo studies in dogs showed a role for A2AAR in CF regulation 
during RH (32), which further confirms the physiological role of adenosine. Zatta et al. 
also confirmed this finding by using pharmacological approaches (11, 167). Furthermore, 
it is proposed that A2AAR contributes to the coronary circulation basal tone since deletion 
of A2AAR and application of SCH58261 (A2A selective antagonist) diminished the 
baseline CF compared to WT hearts (137, 145).  
Due to its lower affinity for adenosine, A2BAR is activated in conditions where a 
significant increase in adenosine levels is observed, such as in ischemia (48). Also, a 
previous study showed that A2BAR may not play a role in basal tone regulation of CF 
since targeted deletion of A2BAR had no effect on the baseline CF (137). Additionally, 
Tune et al. suggested no role for A2BAR in RH by means of indirect measures such as 
using non-selective antagonist (11). Nevertheless, A2BAR is shown to be involved in the 
regulation of CF, albeit may be with a lesser contribution compared to A2AAR (13, 106, 
137, 142). Furthermore, recent studies suggested an interrelationship between A2A and 
A2BARs subtypes since one compensates for the down-regulation/deletion of the other 
(137, 145) through their up-regulation in coronary arterioles. In fact the involvement of 
A2A and A2BARs and their down- or up-regulation is reported in many pathophysiological 
conditions (2, 4, 41, 75). Regardless of this relationship, the differential expression of 
ARs is shown to contribute to functional heterogeneity of human endothelial cells (45) 
and the impairment of adenosine-related signaling contributes to the pathophysiology of 
congestive heart failure (2). By benefiting from gene-modified models and 
pharmacological approaches and by using selective adenosine analogs, we were allowed 
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to better assess the role of A2ARs in the regulation of CF and, therefore, to better 
understand the heterogeneity of CF in relation to A2ARs responses.   
A1AR: There are previous reports from our laboratory suggesting that A1AR 
negatively modulates the role of A2AARs and probably A2BARs in CF regulation (141, 
144). The presence of only A2AARs and A2BARs on coronary endothelial cells may also 
indirectly support this finding (113). Additionally, it was recently reported that in 
Ossabaw swine A1AR antagonism by DPCPX positively regulated basal CF. However, 
although A1AR may not play a major role in CF regulation, it has been shown that this 
receptor mediates negative chronotropic effects which may indirectly affect the CF in 
conditions where adenosine concentration is elevated enough to induce the chronotropic 
effect of this AR subtype. Nevertheless, A1ARs are known to protect the heart from 
ischemia-reperfusion (107, 161, 168) and coronary atherosclerosis (preliminary data from 
our laboratory (146)).  
A3AR: Zhao et al. showed that high concentrations of A3AR agonist, Cl-
IBMECA, induced coronary vasodilation which was further blocked by A2AAR 
antagonism (171). However, A3AR targeted deletion increased the A2AAR-mediated 
response. This finding may suggest that A3AR also participate in CF regulation of 
isolated murine hearts via negative modulation of A2AAR-mediated coronary vasodilation 
(141). Additionally, single-nucleotide polymorphism (SNP) of I248L in A3AR gene is 
shown to be associated with coronary heart disease (120). Further studies are required to 












Classically known signaling of adenosine receptors 
As mentioned, each AR has its own pharmacological profile. Adenosine at its 
basal concentration is sufficient to activate A1, A2A, and A3 ARs. However, due to its low 
affinity for adenosine, A2BARs are activated in conditions where significant high levels 
of adenosine are produced, such as in pathophysiological conditions. It is well established 
that A1 and A3ARs are associated with Gi proteins while A2A and A2B ARs are coupled to 
Gs proteins. The A1 and A3ARs signal through Gi/o proteins and its activation leads to an 
inhibition of adenylyl cyclase (AC) which causes a lowering of cyclic AMP (cAMP) 
levels. The A2A and A2BARs signal through the Gs pathway and its activation leads to 
stimulation of AC resulting in increased production of cAMP. Classically, ARs were 
thought to induce their effects through inhibition (Gi) or stimulation (Gs) of adenylyl 
cyclase. However, it is becoming more and more evident that these receptors also activate 
other pathways such as phospholipase C (PLC), mitogen-activated protein kinase 
(MAPK), etc. In fact, signaling through the A1AR can also lead to activation of IP3/DAG 
through the PLC pathway (68, 143). Additionally, the A2B receptor signals through Gs/q 
and its activation can either result in increased cAMP or IP3/DAG and Ca
2+
 levels. 
Furthermore, ARs are now shown to be associated with the K
+
 channels, production of 




 channels in A2AAR-mediated coronary flow regulation 
K
+
 channels play an essential role in determining the cell membrane potential and 
regulating the contractile tone of arterial smooth muscle cells through controlling the 
Ca
2+
 entry via voltage-dependent Ca
2+
 channels and, thereby, the contractility (67). There 
are four types of K
+ 









 (BKCa), ATP-dependent K
+
 (KATP), and inward 
rectifier K
+
 (Kir) channels. KATP channels are shown to be present on isolated coronary 
artery cells (51, 140), in addition to KV channels which are known to be expressed on 
coronary arteries (33, 66, 140, 156, 166). Additionally, BKCa channels are known to be 
abundantly expressed on coronary smooth muscle cells and contribute to CA vasodilation 
in different species (15, 64, 102), in addition, to Kir channels which are reported to be 
present on both coronary smooth muscle and endothelial cells (119, 126, 140, 157, 166).  
It is worth mentioning that K
+
 was suggested to be the EDHF in various vascular 
beds (39-40). Additionally, in general, K
+
 channels have been suggested to be involved in 
A2A and A2BARs-mediated hyperpolarization of CA (55-56, 74, 109, 112, 137, 170) and 
in adenosine’s role in potentiating flow-induced CA vasodilation (84). Coronary 
arteriolar smooth muscle KATP channels are tonically active under physiological 
conditions. Indeed, in humans as well as in different animal species, application of 
glibenclamide, a KATP channel blocker, resulted in a decrease in resting blood flow (42, 
124-125, 137). Additionally, a primary role for KATP channels in mediating the sustained 
dilation of CA during RH was suggested (167).  
Adenosine is reported to activate KATP channels in rabbit isolated CA smooth 
muscle cells (140) and in the A2A-induced effect in RH (11, 167). Additionally, a recent 
study proposed that the decrease in CF produced by intracoronary glibenclamide may 
cause metabolic changes of ischemia including the release of adenosine (35, 132). This is 
an important observation, since it indicates that blockade of the endogenous vasodilator 
system associated with KATP channel activity can cause coronary vasoconstriction 
sufficient to result in myocardial ischemia (132). Adenosine-mediated activation of KATP 
channels may be indirectly through release of some other mediators such as H2O2 (please 
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see the role of H2O2 in A2AAR-mediated CF regulation section)(50). A study reported 
that the effect of adenosine on endothelial KATP channels may be mediated via pertussis 
toxic-sensitive G proteins and not through the release of NO and cGMP production, 
whereas activation of smooth muscle cell KATP channels may not involve G proteins (59). 
Moreover, the enhanced responsiveness to adenosine at lower CA intraluminal pressure 
was suggested to be due to increased smooth muscle cell KATP channels activity (169). In 
addition to the A2AR-mediated pathway, one study suggested that adenosine also 
activates KATP currents in single CA smooth muscle cells via A1ARs (25). Nevertheless, 
the signaling pathway due to the activation of endothelial KATP channels is yet to be fully 
explored.  
To date no patch clamp study has demonstrated the effect of adenosine on KV 
currents in CA smooth muscle cells. However, in vivo studies have shown that 4-
aminopyridine, KV channel blocker, inhibited CA vasodilation induced by adenosine (11, 
32, 56-58). Previous studies on CA smooth muscle cells also indicate the involvement of 
PKC and PKA in the KV channel-mediated pathway (138, 140),which renders the 
question whether adenosine induces the activation of KV channels through the PKC 
pathway.  
Role of H2O2 in A2AAR-mediated coronary flow regulation 
H2O2 is suggested to act as EDHF in humans and mice (95, 97, 163). 
Additionally, it was reported that H2O2 induces CA vasodilation through both 
endothelium-dependent and –independent manners (147). Recent reports have established 
the contribution of H2O2 in flow-induced dilation of isolated human CA (101) and in 
reactive dilatation of rat isolated coronary arterioles (79). Yada et al. proposed that H2O2 
(as an EDHF in vivo) plays an important role in CA autoregulation in cooperation with 
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adenosine and NO (163). However, so far there are no reports showing the relationship 
between H2O2 and adenosine-mediated coronary vasodilation, which lead to the basis of 
our study. 
It is worth mentioning that Berne’s adenosine hypothesis suggests that increases 
in myocardial oxygen consumption decrease myocardial oxygen tension which leads to 
the stimulation of the release of adenosine from cardiomyocytes (152), where A2AARs 
have also been found to be expressed in both human and mouse (16, 93). Adenosine 
induces CA dilatation through activation of sites on cardiomyocytes in addition to the 
arteriole vascular bed itself (148). Furthermore, as mentioned, a role for H2O2 in 
metabolic vasodilation has already been proposed (164) and Chilian et al. suggested that 
H2O2 production increases in proportion to cardiac metabolism in order to couple the 
coronary blood flow to myocardial oxygen tension (131). What is interesting to 
appreciate is that both H2O2 and adenosine are released from cardiomyocytes and that 
they may modulate the vascular tone through the cardiac myocyte (72). Therefore, 
myocardium may be partly the source of both adenosine and H2O2 released for the 
regulation of CF. Our study is based on such similarities between adenosine and H2O2 
(please also refer to chapter 4).  
Relationship between adrenoceptors (ADR) and A2ARs in coronary flow regulation 
Endogenous adenosine was reported to affect the norepinephrine release from 
sympathetic nerve endings (127). The A2AAR-mediated facilitation of norepinephrine 
release was also suggested to require activation of the PKC and PKA pathways (49) 
which itself is proposed as an adenosine signaling pathway. It was reported that αADR-
mediated coronary vasoconstriction during exercise limits coronary perfusion in impaired 
endothelial function situations (70). DeFily et al. further added to this finding by showing 
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that, even in normal conditions, stimulation of αADR-induced vasoconstriction is masked 
by autoregulatory control, by means of NO release and endogenous adenosine (28). 
Furthermore, it was demonstrated that coronary RH responses due to adenosine are 
blocked by αADRs when NO synthesis is interrupted (14). On the other hand, the 
cardioprotective effect of carvedilol, a βADR blocker, was shown to be through an 
adenosine-dependent mechanism (3). Additionally, it was demonstrated that βADR-
mediated inotropic responses were attenuated by adenosine (134). Therefore, overall 
there is some evidence on similarities between ADR and AR cardiovascular effects and 
signaling. However, there are no studies on the interaction or cross talk of ARs and 
ADRs in the regulation of CF which was the basis of our new study (Please see our 
appendix A). 
Clinical applications  
Adenosine and its agonist are currently being used in clinical settings; The 
vasoregulatory properties of A2AARs are used clinically in humans for the diagnosis of 
coronary artery disease through the use of adenosine (Adenoscan) as a substitute for 
exercise stress testing for people who can’t exercise in myocardial perfusion imaging 
(12). The use of Adenoscan has its own limitations due to its blocking effect on AV 
conduction [due to activation of A1ARs (10, 12)] and inducing bronchospasm [probably 
due to activation of A1, A3 or A2BARs (47, 123)]. However, these side effects may be 
alleviated by the development of more A2ARs subtype selective agonists. A new A2AAR 
selective agonist called Regadenoson (Lexiscan®) has been developed and approved by 
FDA which is being used clinically in myocardial perfusion imaging. Additionally, in 
many cardiovascular diseases such as coronary atherosclerosis, angina, and hypertension, 
an attenuated vascular response to adenosine has been demonstrated where functional 
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disturbance of smooth muscle or endothelial cells may be the underlying cause. 
Therefore, it is important to better understand adenosine’s role in the regulation of CF, its 





 Project Summary 
Adenosine plays an important role in coronary flow regulation in physiological and 
pathological conditions where AR expression modification may occur. Therefore, the 
purpose of this investigation was to better understand the individual role and contribution 
of A2ARs in the regulation of coronary flow and their mechanism of action during their 
exogenous and endogenous activation. In addition to better understand the heterogeneity 
of CF responses by ARs, elucidation of ARs’ role in CF regulation would enable us to 
develop therapies with less unwanted side effects or new enhanced medications for the 
diagnosis and/or treatment of cardiovascular disorders. With this purpose in mind, the 
following aims were developed: 
 
Specific Aim 1: Elucidation of the role of A2 ARs in the regulation of coronary flow 
Specific Aim 2: Identification of A2 ARs signaling pathways in coronary flow 
regulation 
Specific Aim 3: Characterize the role of A2 ARs in coronary reactive hyperemia 
Specific Aim 4: Identify the role of H2O2 in A2 ARs’ signaling pathway during 
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The isolated perfused heart (Langendorff heart system), especially for small 
animals, is one of the optimal approaches, having in mind, the quantity and quality of 
data that can be obtained in a laboratory setting. Nevertheless, this approach has its own 
advantages and disadvantages.   
The isolated heart provides us with types of data, such as heart rate, left ventricle 
pressure, and coronary flow, in the absence of the confounding effects of other 
organs,systemic circulation, neurohormonal factors, etc. This characteristic is considered 
as an advantage since it allows the distinction of aforementioned factors from cardiac 
responses. The absence of neurohormonal and peripheral factors can often be 
compensated for, if required; for example catecholamines or other neurotransmitters may 
be included in perfusate and many other peripheral mediators can be added exogenously. 
However, this approach can also be considered a disadvantage in the sense that it makes 
the preparation one step further away from the physiological in vivo state. Nonetheless, 
without a doubt, the isolated heart system provides us with the ability of performing 
metabolic or pharmacological dose-response studies. Although one must take into 
account the fact that, as an ex vivo preparation, the isolated heartundergoes deterioration 
in time, but it is capable of providing data up to 3-4 hours. 
Using the isolated heart system, we are also able to induce whole heart ischemia 
through flow occlusion; this is an approach that we used for our reactive hyperemia 
experiments. Anoxia or hypoxia at various degrees of oxygen deprivation (in the 
presence of normal flow) can also be easily imposed through manipulation of 
oxygenation rate or amount. Therefore, this approach provides us with a powerful tool for 
assessing many aspects of ischemia/hypoxia or even, if interested, ischemia-reperfusion-
induced injury, in which case single coronary occlusion can be performed.  
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It is important to know that we have two modes of operation of the isolated 
perfused heart systems: constant flow and constant pressure. Whereas constant flow 
perfusion eliminates a variable from the experiment, it also has the disadvantage that, 
unlike constant pressure perfusion, autoregulatory coronary flow mechanisms are 
overridden and, therefore, it does not provide us with data regarding coronary flow 
regulation. Switching between constant flow and constant pressure modes of perfusion is 
not very straightforward so that it can be feasible within a single experimental protocol. 
However, currently, this system is now commercially available through ADInstruments 
Ltd. which allows us to switch instantly between constant pressure and constant flow 
modes of perfusion, enabling perfusion pressures and coronary flow to be controlled over 
a wide range. This feature is of considerable advantage in many studies of vascular 
function. 
Using isolated perfused heart, several types of data can be gathered; for the 
purpose of morphology and vascular anatomy studies, heart or vascular fixation can be 
easily performed through coronary perfusion of required agents and a sequential analysis 
using light or electron microscopy. Additionally, the heart can be sliced, starting at the 
apex of the heart and working towards the base, for histology studies of coronary arteries. 
The whole heart can also be used for gross morphology such as is required during infarct 
size or cardiac hypertrophy studies. From a biochemistry/physiology point of interest, 
arterio-venous substrate concentration differences for metabolites, oxygen, and a host of 
other factors involved during physiological and extreme metabolism can be measured. 
Additionally, measurement of cellular constituents such as enzymes and proteins can be 
performed for the assessment of tissue injury due to the influence of, for example, various 
conditions such as ischemia/reperfusion or hypoxia. Microelectrodes can further be used 
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, pH or monophasic action potentials. 
With all that in mind, using isolated heart perfusion the coronary perfusion, can be used 
for delivery of vectors in gene transfer studies where adenovirus or other vectors can be 
selectively delivered to the coronary artery vasculature and hence providing us with a so 
called “organ specific gene modification”, which may replace whole animal knockout 
models as an approach which may exclude the effect of compensatory mechanisms due to 
the general whole animal gene modification. 
From a more functional standpoint, using the isolated heart system, 
electrocardiographic recordings allow the detection, identification, and quantification of 
cardiac arrhythmias. Furthermore, the Langendorff preparation provides valuable 
information on left ventricular systolic and diastolic pressures and derivatives such as 
dp/dt. Various ultrasound techniques, such as echocardiography and Doppler, can also be 
used for measurements of cardiac wall thickening, stroke volume, cardiac output, 
coronary flow velocity, etc. While most studies with the isolated perfused heart are 
focused on the function and malfunction of the cardiomyocyte, using contractile and 
metabolic endpoints, it should be highlighted that Langendorff heart system can be used 
to study vascular reactivity, endothelial and smooth muscle function, and the effect of a 
variety of agents and drugs on coronary flow. Indeed, the isolated heart has been the 
foundation of much of the work on the no reflow phenomenon where A2ARs agonists are 
currently being clinically investigated as an approach for reduction of reperfusion injury. 
Nevertheless, even from basic therapeutic approaches, the isolated heart preparation is 
reliable for assessing the direct cardiovascular effects of various therapeutic agents in 
terms of contractile function, electrical activity, or metabolic function. This preparation 
allows us to perform dose-response studies with reproducibility and precise control of 
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agent concentration. An additional advantage is that we are able to washout drugs from 
the circulation by replacing perfusion fluids which itself can be an excellent approach to 
study drug tachyphylaxis or desensitization. 
There are also further important issues to consider when using the isolated heart 
system. Like so many other aspects of heart perfusion, the decision of whether to pace the 
heart or not, is based on a compromise between protocol requirements and quality of 
data. Heart rate in isolated hearts, when left to contract spontaneously, undergoes a 
progressive time-dependent decline. Spontaneous heart rate, in a perfused heart system, is 
usually significantly below the physiological normal rate. Mouse heart rate, in an in vivo 
preparation, is about 500 beats/min, whereas heart rate of about 380 beats/min, can be 
expected in the ex vivo preparation. This decline in baseline heart rate, of course, adds an 
additional variable, which itself may also vary among the animals. Moreover, this decline 
in heart rate also adds variability to the measurements obtained for left ventricular 
pressure. During an experiment, the worsening of HR depends on a large number of 
factors including the skills of the worker, avoidance of injury, the species being used, the 
composition of the perfusion fluid, the drugs used, age, HR and work load, and the 
temperature at which the studies are carried out. During a Langendorff heart preparation 
experiment, a deterioration rate of contractile function of about 5-10% per hour is 
expected. Therefore, the rate of deterioration should be taken into account for the 
interpretation of studies and the experiments should be more or less time-matched with 
corrections for baseline deterioration when comparing groups. 
Use of the isolated heart perfusion approach is reported in many large animals 
such as pigs, monkeys, sheep, dogs and even humans. Nevertheless, such studies are less 
frequently performed due to many limiting factors such as high cost, presence of greater 
53 
 
variability in results, need forf large volumes of perfusion fluid and specialized 
equipment required. The availability of transgenic technology for mice undoubtedly 
resulted in increasing numbers of studies using murine preparations. Indeed, one of the 
reasons to use mouse, in our laboratory, was the availability of AR KO mice. Currently, 
the literature consists of an increasing number of studies which employ mouse hearts 
although the high HR ofmice may set some limitations for translation of data obtained 
from this species to human studies. Another limitation in the use of mice, in some studies, 
is the very small size of all organs or tissues. For example, the size of many arteries, such 
as large conduit coronary arteries, is in ~80 µm range, which shows a very smaller size 
range for the coronary resistance vessels. The size of these vessels somehow limits the 
study of coronary arteries in that the isolation of the actual resistance vessels is extremely 
challenging. Also, the use of a larger number of animals is required in order to obtain 
sufficient amount of tissue for the purpose of even basic experiments such as RT-PCR or 
western blot. Another limitation with the use of mice is the miniaturization of equipment; 
handling of rat hearts, for example, has a great advantage over smaller hearts from mice 
where intraventricular pressure recordings are more difficult. The rat does, however, 
suffer from very short action potential duration which can limit its value in terms of 
translation of data to human studies of arrhythmia and antiarrhythmic drugs. Other 
species, such as the rabbit, suffer problems with anesthesia and the guinea-pig heart 
differs from other species in that the coronary vasculature is totally collateralized, 
effectively preventing the study of regional ischemia in this species. Thus, as no ideal 
species or setting exists, in selecting a species or preparation for a specific study, it is 
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Adenosine plays a role in physiological and pathological conditions and A2 adenosine 
receptors (AR) expression is modified in many cardiovascular disorders. In this study, we 
elucidated the role of A2BAR and its relationship to A2AAR in coronary flow (CF) 
changes using A2B single (KO) and A2A/2B double (DKO) knockout mice in Langendorff 
setup. We used two approaches: a) selective and non-selective AR agonists and 
antagonists, and b) A2A and A2BKO and A2A/2BDKO. BAY60-6583 (selective A2B 
agonist) had no effect on CF (ml/min/g) in A2BKO while it significantly increased the 
WT CF (maximum of 23.3±9). NECA (non-selective AR agonist) increased the CF in 
A2BKO (maximum of 34.6±4.7) to a significantly higher degree compared to WT 
(maximum of 23.1±2.1). Also, CGS21680 (selective A2A agonist) increased the CF in 
A2BKO (maximum of 29±1.9) to a significantly higher degree compared to WT 
(maximum of 25.1±2.3). SCH58261 (A2A selective antagonist) inhibited the NECA-
induced increase in CF to a significantly higher degree in A2BKO (19.3±1.6 vs. 0.5±0.4) 
compared to WT (19±3.5 vs. 3.6±0.5). NECA did not induce any increase in CF in 
A2A/2BDKO while a significant increase was observed in WT (maximum of 23.1±2.1). 
Furthermore, mitochondrial KATP channel blocker 5-hydroxydecanoate had no effect on 
NECA-induced increase in CF in WT while NECA-induced increase in CF in WT 
(17.6±2), A2AKO (12.5±2.3), and A2BKO (16.2±0.8) was significantly blunted by KATP 
channel blocker, glibenclamide, to 0.7±0.7, 2.3±1.1, and 0.9±0.4, respectively. Also, 
CGS21680 (22±2.3), and BAY60-6583 (16.4±1.60)-induced increase in CF in WT was 
significantly blunted by glibenclamide to 1.2±0.4 and 1.8±1.2, respectively. In 
conclusion, this is the first evidence supporting the compensatory up-regulation of 
A2AAR in A2BKO mice and demonstrating that both A2A and A2BARs induce CF changes 
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through KATP channels. These results identify AR-mediated CF responses which may 
lead to better therapeutic approaches for the treatment of cardiovascular disorders. 
 
Introduction 
Adenosine is an endogenous nucleoside which is released through the breakdown 
of adenine nucleotides. Adenosine’s cardiovascular effects are mediated through 
activation of its four subtypes of receptors (AR), namely, A1, A2A, A2B and A3. Activation 
of A1AR results in negative chronotropic and ionotropic effect, and a decrease in 
coronary flow (CF) (68) while other studies suggest that the activation of both A1 or 
A3ARs prior to ischemia is cardioprotective (6, 30). However, adenosine is shown to play 
a vasoregulatory role in human coronary arteries (16-17, 62-63). It is well established that 
the activation of A2AAR induces positive inotropic effect and that A2AAR plays a major 
role in the regulation of CF in ex vivo models (67, 69). Additionally, in vivo studies in 
dogs showed the involvement of A2AAR in CF (reactive hyperemia) regulation (5, 77) 
and thus, supporting a physiological role for adenosine. Adenosine-induced effects are 
species-dependent (20, 23). For example it is reported that guinea pig coronary 
vasodilation is more sensitive to adenosine compared to rats (72). Furthermore, few 
studies show that A2BAR acts as a vasoconstricting as well as a vasodilating factor in 
different vascular beds (13, 57), in addition, to playing a cardioprotective role during 
ischemia/reperfusion (14-15, 30). Nevertheless, there are no reports fully elucidating the 
individual and relative role of A2BAR in relation to A2AAR in coronary vasodilation. Our 
group and others have previously suggested a role for A2BAR in coronary artery 
vasodilation by means of indirect measures such as using non-selective agonist and 
antagonists and A2AKO mice (48, 67) which are in accordance with previous reports 
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showing A2AR-mediacted vasodilation in isolated human coronary arteries (39, 63). 
Furthermore, this laboratory has shown the presence of A2B and A2AARs in human and 
porcine coronary artery endothelial and vascular smooth muscle cells that may further 
support the involvement of A2A and A2BARs in the regulation of CF and a further possible 
interaction between these two receptor subtypes (53, 71). Coexpression of more than one 
AR subtype is also reported from other laboratories on human endothelial cells (36, 53) 
however, there are no reports studying whether the coexpressed receptors interact. We 
have recently shown an up-regulation of A2BAR in A2AKO mouse coronary artery 
suggesting an interrelationship between A2A and A2BARs subtypes since A2BAR 
compensated for the down-regulation/deletion of A2AAR (69). Additionally, since the 
involvement of A2A and A2BARs and their down- or up-regulation is reported in many 
pathophysiological conditions (2, 40) and differential expression of ARs contributes to 
functional heterogeneity of human endothelial cells (21), elucidating the presence of such 
compensatory mechanisms and signaling pathways for ARs is essential for better 
understanding of the heterogeneity of vascular responses and the regulation of CF.  
While A2BAR is reported to induce its cardiovascular effects through activation of 
arachidonic acid pathway in vasculature (13), A2AAR-induced vascular effects are 
demonstrated to partly involve CYP expoxygenases (50).  We and others have previously 
demonstrated that A2AAR-induced vasodilation is partly due to release of nitric oxide in 
mouse aorta and coronary arteries (69). However, A2BAR-induced vasodilation is both 
nitric oxide-dependent and –independent in mouse aortic conduit artery and coronary 
arteries, respectively (1, 69). Although KATP channels are shown to be present in coronary 
artery cells (28, 65) and K
+
 channels in general are known to be involved in A2A and 
A2BARs-mediated hyperpolarization of coronary arteries (31, 39, 52), the involvement of 
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KATP channels in adenosine-induced coronary artery responses remains poorly 
understood.  
The purpose of the present study was to directly and more fully elucidate the 
individual contribution of A2BAR and its relationship to A2AAR in A2ARs-mediated 
induction of coronary artery vasodilation in light of the KATP channel involvement. The 
hypotheses to be tested were; a) A2BAR contributes to coronary vasodilation, b) A2A and 
A2BARs interact to induce coronary artery vasodilation and they each compensate for the 
deletion/down-regulation of the other, and c) A2A and A2BARs-induced increase in CF is 
the result of activation of KATP channels. Since there are inconsistencies between the 
results obtained from transgenic models compared to those obtained using 
pharmacological approaches (55), in this study, we have used both pharmacological and 
molecular (targeted gene deleted mouse model) approaches. Furthermore, we used 
A2A/2BDKO mice to remove any possible compensatory up-regulation of either A2A or 
A2BAR in CF responses. 
 
Methods 
All experimental protocols were performed according to the West Virginia 
University guidelines and approval of Animal Care and Use Committee. 
Generation of DKO mice.  A2A -/- mice (backcrossed 12 generations to the C57BL/6 
background) were bred with A2B -/- mice (backcrossed 12 generations to the C57BL/6 
background) to generate A2A +/- A2B +/- double heterozygotes. These double 
heterozygotes were then intercrossed, and 1/16 of the resultant offspring were A2A -/-A2B 
-/- DKOs.  Male and female DKO breeding pairs were established from these animals to 
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produce DKO mice.  Since both A2A -/- and A2B -/- mice were inbred on C57BL/6, DKO 
are also inbred.  
WT, A2A, and A2BKO and A2A/2BDKO mice. Hearts were isolated from age-matched 
10 to 14 weeks old mice. WT mice of a mixed C57BL/6 genetic background were 
purchased from The Jackson Laboratory (Bar Harbor, Maine). A2BKO and A2A/2BDKO 
mice of the same background were generously provided by Dr. Stephen Tilley, 
Department of Medicine, University of North Carolina, Chapel Hill, NC. A2AKO mice of 
the same background were generously provided by Dr. Catherine Ledent, Universite 
Libre de Bruxelles, Brussels, Belgium. All four strains were bred at the West Virginia 
University animal facility as a sub-colony of the original strain. The mice were kept in 
cages with 12:12-hr light-dark cycles and maintained on a standard laboratory diet with 
access to water ad libitum. All animal care and experimentation were in accordance with 
the West Virginia University Institutional Animal Care and Use Committee and the 
principles of the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals.” 
Chemicals. All chemicals were prepared as 10 mM stock using Dimethyl 
Sulfoxide (DMSO, Sigma) followed by serial dilution with 50% DMSO and distilled 
water and further dilution to desired concentration was achieved with distilled water 
(final DMSO concentration of < 1%).  NECA (5'-N-ethylcarboxamido adenosine), 
CGS21680, 5-hydroxydecanoate, and glibenclamide were bought from Sigma (St. Louis, 
MO, USA) and SCH58261 was a gift from Schering-Plough, Italy. A2B agonist, BAY60-
6583, was a gift from Bayer (Germany). All stated concentrations are the actual drug 
concentration delivered as 1% of coronary flow. 
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Langendorff-perfused mouse heart preparation. Isolated heart experiments were 
performed in accordance with the methods published earlier from our lab (48). In brief, 
mice were anesthetized with intraperitoneal sodium pentobarbital (50 mg/kg). A 
thoracotomy was performed, and the hearts were removed into heparinized (5U/ml) ice-
cold Kreb-Hensleit (KH) buffer. The hearts were retrogradely perfused rapidly through 
the aorta cannulated with a 20-gauge, blunt-ended needle at a constant pressure of 80 
mmHg with continuously gassed with 95% O2 and 5% CO2 KH buffer containing (mM): 
119 NaCl, 11 Glucose, 22 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2 
Pyruvate and 0.5 EDTA at 37°C in a standard Langendorff fashion and allowed to beat 
spontaneously. The left atrium was removed and the left ventricle was vented with a 
small polyethylene apical drain. A water-filled balloon made of plastic wrap was inserted 
into the left ventricle across the mitral valve, which was connected to a fluid-filled 
pressure transducer by polyethylene tubing for continuous measurement of left 
ventricular developed pressure (LVDP). Left ventricle diastolic pressure was adjusted to 
a pressure of 2-5 mmHg by filling up the left ventricle balloon. Coronary flow was 
measured via a Transonic flow probe (Transonic Systems; Ithaca, NY) in the aortic 
perfusion line. Baseline coronary flow, LVDP, and heart rate (derived from the 
ventricular pressure trace) were monitored for 30 min during the equilibration period, 
which were recorded on a Power Lab data acquisition system (AD Instruments; 
ColoradoSpring, CO). Hearts with persistent arrhythmias or poor LVDP (<80 mmHg) 
during the equilibration period were excluded from the study. To rule out the 
tachyphylaxis or desensitization, at the end of each antagonist experiment, after another 
washout period, a repeat infusion of the agonist was performed.  
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UExperimental Protocols. After 30 minutes of equilibrium, baseline coronary flow, heart 
rate, and developed pressure were measured in WT, A2BKO, and A2A/2BDKO isolated 




M) were performed for BAY60-
6583 (A2B selective agonist), NECA (non-selective AR agonist) and CGS21680 (selective 
A2A agonist) by infusing the drugs into the coronary perfusate through an injection port 
directly proximal to the aortic cannula using a microinjection infusion pump (Harvard 
Apparatus; Holliston, MA). After equilibration period, each heart was perfused with 
increasing concentration of selected drug to develop a concentration-response 
relationship curve. Each drug concentration was given for 5 min with 10 min intervals to 
allow complete drug washout (or using recovery to baseline parameters). All 
concentrations are the actual concentration in the perfusate. Data were collected at the 
end of each infusion period and washout time, which was used as a reference for 
normalizing responses to the subsequent drug concentration. In the result section, actual 
values from CRCs (figures 1-2,4, and 6) are presented as the maximum response and 
values from the use of a single drug concentration in the presence and absence of an 
antagonist (Figures 5 and 7-9) are presented as the actual drug-induced effect (maximal 
response minus the baseline).  
UAntagonist experiment protocol. U After 30 min equilibration period and measurement of 
baseline parameters, agonists, NECA (10
-8
M, in A2B KO mice, or 10
-8
M, in A2A KO 
mice, closest concentration to the EC50 obtained from previously performed experiments) 
(Figures 7 and 8), BAY60-6583 (10
-7
M) (Figure 9), and CGS21680 (5x10
-9
M) (Figure 9), 
were infused for 5 min at 1% rate of coronary flow. The plateau effect of coronary flow, 
heart rate, and developed pressure were recorded and a 10 min washout interval was 





M, A2A selective antagonist) (71) (Figure 5) or glibenclamide (10
-5
M) (Figures 7-9), 
at 1% rate of coronary flow for at least 10 min after which, the agonist was also added to 
the infusion line for an additional 5 min (for a total of 15 min). The baseline at the end of 
antagonist infusion was treated as the new baseline for the subsequent agonist responses. 
The data at the end of the 15 min (the end of infusion of both agonists and antagonists) 
were used to compare with data obtained from the first infusion of the agonist alone. At 
the end of the experiment, after at least 10 min of washout and reaching the baseline, the 
agonist was again infused in order to check for tachyphylaxis or desensitization.  
Western Blot. Mouse mesenteric arterioles (up to third branch arterioles) 
homogenates were obtained from isolated and cleaned tissue using ice-cold lysis buffer 
consisting of 0.05 M Tris-buffered saline, pH 7.4, 1% Triton X-100, 0.25% sodium 
deoxycholate, 150 mM sodium chloride, 1 mM EDTA, 1 mM phenylmethylsulfonyl and 
Halt Protease Inhibitor Cocktail (Thermo Scientific) by way of glass homogenizer.  
Samples were then centrifuged for 15 min at 13,000 rpm and the supernatant was stored 
at -80°C.  Protein extracts (30 μg protein per well) were separated on NuPAGE 4-12% 
Bis-Tris Gels (Invitrogen) along with Novex Sharp Protein Standard, 3.5–260-kDa, 
(Invitrogen) run in parallel.  Proteins were then transferred to a PVDF membrane 
(Millipore), blocked in 5% milk for 1 hour and then probed with anti-A2AAR Rabbit 
Polyclonal IgG antibody (45) developed in our laboratory for detection of A2AAR protein 
with a dilution of 1:1000 in TBST + 0.5% milk overnight at 4°C or with anti-β-actin 
(Santa Cruz Biotechnology) at a dilution of 1:5000 at room temperature for 1 hour.  This 
was followed by incubation with a secondary horseradish peroxidase-conjugated 
antibody (anti-mouse and anti-rabbit immunoglobulins, respectively; Santa Cruz 
Biotechnology Inc.) for 1 h at room temperature. For detection of bands, the membranes 
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were treated with an enhanced chemiluminescence reagent (GE Healthcare) for 1 min and 
subsequently exposed to ECL Hyperfilm (GE Healthcare).  Relative band intensities were 
quantified by densitometry, and each sample was normalized to the β-actin values and 
calibrated to A2AAR protein expression in WT. 
Data and Statistical analysis. Western blot data and baseline functional data of 
A2AKO, A2BKO, and A2A/2BDKO groups were compared to WT, analyzed by using t-test. 
Differences in dose response curves and responses to each drug at the same concentration 
between WT, A2BKO, A2AKO, and A2A/2BDKO hearts were analyzed using two-way 
ANOVA for repeated measures. Antagonist-induced responses (HR, LVDP, and CF) for 
WT, A2AKO, and A2BKO hearts were compared with t-test. Statistical comparisons were 
done on percent changes. Results were considered significant when P < 0.05. Values are 




Baseline function in WT, A2AKO, A2BKO, and A2A/2BDKO isolated hearts. Table 1 
demonstrates the baseline parameters for coronary flow (CF), heart rate (HR), and left 
ventricle developed pressure (LVDP) for A2AKO, A2BKO, A2A/2BDKO, and WT mice 
after 30 min of equilibration of the isolated hearts as mentioned in the “materials and 
methods”. The average body weight of A2BKO mice was significantly lower compared to 
the WT while heart weight to body weight ratio were not significantly different in any 
KOs compared to WT. Furthermore, no significant baseline differences were observed in 
CF and HR in any of the KOs compared to WT while LVDP was significantly higher in 
A2A/2BDKO compared to WT hearts (Table 1).  
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Effect of A2BAR activation on coronary flow. BAY60-6583 (A2B selective agonist) 
caused a concentration-dependent increase in CF in WT whereas no effect was observed 
in A2BKO mice (Figure 1A). BAY60-6583 increased the CF in WT mice (with a 
maximum of 23.3±9ml/min/g, n=7) to a significantly higher degree compared to A2BKO 
(no response) (Figure 1A). BAY60-6583 had no effect on HR of either WT or A2BKO 
(Figure 1B) while it induced a significant increase in LVDP from baseline in the WT 
animals to a maximum of 95.6±14.9 mmHg (Figure 1C, n=7). BAY60-6583 had no effect 
on LVDP in A2BKO hearts (Figure 1C).  
Contribution of A2AAR in ARs-mediated coronary vasodilation of A2BKO mice. 
Since we wanted to test if A2AAR compensates for A2BAR in producing coronary 
vasodilation in A2BKO mice, we used NECA (non-selective AR agonist) in A2BKO and 
WT mice. NECA increased the CF in A2BKO mice (with a maximum of 
34.6±4.7ml/min/g, n=8, and EC50: 6.8x10
-9
±0.8M) to a significantly higher degree 
compared to WT mice (with a maximum of 23.1±2.1ml/min/g, n=9, and EC50: 3.5x10
-
9
±0.6M) (Figure 2A). Furthermore, NECA induced a significant increase in LVDP of 
A2BKO compared to WT with a maximum increase of 115.5±8.5mmHg and 
77.5±11.6mmHg, respectively (Figure 2C), while a decrease in HR was noted in both 
WT and A2BKO mice with no significant difference between the two groups (Figures 
2B). 
Up-regulation of A2AAR expression in A2BKO isolated mesenteric arterioles. We 
used mesenteric arterioles as resistance vessels to analyze A2AAR expression level in 
A2BKO mice. The A2AAR protein was significantly increased in A2BKO isolated 
mesenteric arterioles compared to WT (25.7% higher expression, Figure 3, n=4, p<0.05)  
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Up-regulation of A2AAR in A2BKO mice. CGS21680 increased the CF (ml/min/g) 
in A2BKO mice (27.2±2.6 at 5x10
-8
M and 29±1.9 at 10
-7
M with EC50: 3.9x10
-9
±0.7M, 
n=7) to a significantly higher degree compared to WT (22.4±1.5 at 5x10
-8
M and 25.1±2.3 
at 10
-7
M with EC50: 2.6x10
-9
±0.7M, n=7) (Figure 4A). Additionally, CGS21680 caused a 
significant increase in LVDP (mmHg) in A2BKO (111.5±6.7 at 5x10
-8
M and 113±8.1 at 
5x10
-7
M) compared to WT (97.9±4.9 at 5x10
-8
M and 93±6.1 at 5x10
-7
M) while there 
were no difference between the HR induced by CGS21680 when comparing WT and 
A2BKO (Figures 4B-C). 
Up-regulation of A2AAR in A2BKO mice. To further confirm the up-regulation of 
A2AAR in A2BKO mice as a compensatory response for the regulation of CF, we used 
SCH58261, A2A selective antagonist, and tested its effect on NECA (10 nM)-induced 
increase in CF in WT and A2BKO. SCH58261 (1 µM) significantly decreased the 
baseline CF (ml/min/g) of WT (from 9.9±0.7 to 6.8±0.7) and A2BKO (from 12.3±0.6 to 
7.7±1.1, (Figure 5A).   SCH58261 also caused a significantly higher inhibition of NECA-
induced increase in CF (ml/min/g) in A2BKO (19.3±1.6 vs. 0.5±0.4 n=4) compared to WT 
(19±3.5 vs. 3.6±0.5, n=6) (Figure 5A). NECA at 10 nM concentration and SCH58261 
had no significant effect on HR in both WT and A2BKO animals (Figure 5B). However, 
NECA significantly increased the LVDP (mmHg) in both A2BKO (from 99.9±11.5 to 
141±20.8, n=4) and WT (from 89.5±4.4 to 123.1±4.5, n=6) hearts (Figure 5C). 
SCH58261 significantly reduced the baseline LVDP (mmHg) in both A2BKO (from 
99.9±11.6 to 84.2±12.2) and WT (from 89.5±4.4 to 80.6±5.2) hearts. Additionally, 
SCH58261 significantly reduced the NECA-induced increase in LVDP in both A2BKO 
and WT groups (34.9±5.9 vs. 2.8±1.5, n=4, and 33.6±5.7vs. 6.7±4, n=4, respectively) 
compared to their respective controls (Figure 5C). 
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Involvement of A2A and A2BARs in producing coronary vasodilation. In order to 
rule out the compensatory response between A2A and A2BARs, NECA was used in 
A2A/2BDKO mice (Figure 6). NECA did not induce any increase in CF in A2A/2BDKO 
(n=5) while a concentration-dependent response was observed in WT with a maximum 
increase up to 23.1±2.1ml/min/g (n=9) (Figure 6A). Additionally, NECA-induced effect 










6C). However, the decrease in HR in WT was not different compared to A2A/2BDKO 
hearts (Figure 6B).  
Involvement of KATP channels in A2A and A2B ARs-induced increase in coronary 
flow. We used 5-hydroxydecanote (mitochondrial KATP channel blocker, 10
-4
M) to test its 
effect on NECA (10
-8
M)-induced increase in CF in WT mice. The NECA concentrations 
were chosen based on the EC50 obtained from previously performed experiments (10
-8
M 
in WT and A2BKO and 5x10
-8
M in A2AKO). 5-hydroxydecanote had no effect on NECA-
induced increase in CF (ml/min/g) (15.3±2.8 vs. 18.5±3.1, n=5, Figure 7A). Additionally, 
5-hydroxydecanote had no effect on NECA-induced changes in HR and LVDP (Figures 
7B-C). Furthermore, we used glibenclamide (KATP channel blocker) to test its effect on 
NECA-induced increase in CF in WT, A2A and A2BKO mice (Figures 7A and 8A). 
Glibenclamide significantly reduced NECA-induced increase in CF (ml/min/g) in WT 
(17.6±2 vs. 0.7±0.7, n=4, Figure 7A), A2AKO (12.5±2.3 vs. 2.3±1.1, n=5, Figure 8A), and 
A2BKO (16.2±0.8 vs. 0.9±0.4, n=5, Figure 8A). However, glibenclamide did not change 
NECA-induced effect on HR (bpm) in A2A and A2BKO while it significantly reduced the 
NECA-induced effect on HR in WT compared to its control (28.5±9.7 vs. -8.1±7.6) 
where it also significantly reduced the basal HR from 315.5±11.1 to 236.6±15.2 (Figures 
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7B and 8B). Furthermore, glibenclamide did not change NECA-induced effect on LVDP 
in A2AKO while significantly reduced the LVDP (mmHg) in WT (26.4±9.9 vs. 1.2±3.6) 
and A2BKO (16.7±3.3 vs. 2.4±2.3, n=5) (Figures 7C and 8C). To confirm the effect of 
glibenclamide we tested its effect on pinacidil (KATP channel opener as positive control). 
Glibenclamide significantly reduced pinacidil-induced increase in CF (ml/min/g) from 
baseline in WT (19±3 vs. 10.2±1.8, n=6). However, glibenclamide did not change 
pinacidil-induced effect on HR and LVDP in WT mice (Figure 7). 
Additionally, we tested the effect of glibenclamide on CGS21680 (A2A selective 
agonist) and BAY60-6583(A2B selective agonist)-induced increase in CF in WT (Figure 
9A).  Glibenclamide significantly reduced the effect of CGS21680 (5x10
-9
M) (22±2.3, 
n=5) and BAY60-6583 (10
-7
M) (16.4±1.6, n=4) on CF (ml/min/g) to 1.2±0.4 (n=5) and 
1.8±1.2 (n=4), respectively (Figure 9A). In the presence of glibenclamide both the 
baseline and drug-induced effects on HR were significantly decreased compared to their 
control (Figure 9B). Additionally, glibenclamide significantly reduced CGS21680 and 
BAY-induced increase in LVDP (mmHg), 31.6±13.1 vs. 1.9±4.7 (n=5) and 20.1±1.7 vs. 




Figure 3.1 Effect of BAY 60-6583 (BAY) in A2BKO and WT mice on coronary flow 
(A), heart rate (B) and LVDP (left ventricle developed pressure) (C). *Significant 
difference compared to WT, p<0.05. 









































































Figure 3.2 Effect of NECA in A2BKO and WT mice on coronary flow (A), heart rate 
(B), and LVDP (C). *Significant difference compared to WT, p<0.05. 















































































Figure 3.3 A2AAR expression levels in WT and A2BKO isolated mesenrteric 
arterioles.*Significant difference compared to WT, p<0.05. 
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Figure 3.4 Effect of CGS 21680 in A2BKO and WT mice on coronary flow (A), heart 
rate (B), and LVDP (C).*Significant difference compared to WT, p<0.05. 




































































Figure 3.5 Effect of SCH 58261(1µM) on NECA-induced increase in coronary flow 
(A), heart rate (B), and LVDP (C) in WT and A2BKO. *Significant difference 
between drug-induced effects in the presence of antagonist compared to their 
corresponding control. 
#
Significant difference in baselines in the presence of 
antagonist compared to their corresponding control. 
$
Significant difference between 
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Figure 3.6 Effect of NECA in A2A/2BDKO and WT mice on coronary flow (A), heart 
rate (B), and LVDP (C). *Significant difference compared to WT, p<0.05. 











































































Figure 3.7 Effect of 5-hydroxydecanote (5-HD) on NECA-induced increase in 
coronary flow (A), heart rate (B), and LVDP (C) in WT and the effect of 
glibenclamide (GB) on NECA and pinacidil (PIN)-induced increase in coronary flow 
(A), heart rate (B), and LVDP (C) in WT.*Significant difference in drug-induced 
effects in the presence of antagonist compared to their corresponding control. 
#
Significant difference in baselines in the presence of antagonist compared to their 




































































































































Figure 3.8 Effect of glibenclamide (GB) on NECA-induced increase in coronary flow 
(A), heart rate (B), and LVDP (C) in A2A KO and A2B KO. *Significant difference in 
























































































































Figure 3.9 Effect of glibenclamide (GB) on CGS 21680 (CGS) and BAY 60-6583 
(BAY)-induced increase in coronary flow (A), heart rate (B), and LVDP (C) in WT. 
*Significant difference in drug-induced effects in the presence of antagonist 
compared to their corresponding control. 
#
Significant difference in baselines in the 





























































































































Body weight, g           25±0.6 25±1.2 23.8±0.6* 24.7±1.1 
Heart weight, g 0.1 0.1 0.1 0.1 
Heart-to-body 
weight ratio, % 
0.5±0.4 0.4 0.4±0.1 0.4 
Coronary flow, 
ml.min-1.g-1 
15.2±0.8 17.2±0.9 14.5±0.7 15.6±1.8 
Heart rate, 
beats/min 
341.6±10.3 356.8±14.5 345.1±7.8 330.4±17.8 
Developed 
pressure, mmHg 
80.3±4.2 81.2±4.8 83.3±3.3 97.1±6.2* 
 
All parameters were collected after 30 min of equilibration in langendorff preparation. 




















In this study we have further elucidated the contribution of A2BAR and its 
relationship to A2AAR in A2ARs-mediated coronary artery vasodilation. With the use of 
A2A/2BDKO mice, we also showed for the first time that A2A and A2BARs, out of four 
ARs subtypes, contribute to coronary artery vasodilation and down-regulation/deletion of 
either of A2A and A2BARs leads to a compensatory up-regulation of the other AR and 
thus, suggesting an interrelationship between these two receptor subtypes. Furthermore, 
we showed for the first time the involvement of non-mitochondrial KATP channels in 
A2BAR-mediated coronary artery vasodilation, and finally showed the direct involvement 
of KATP channels in A2AAR-mediated increase in coronary flow using AR KO mice.  
Adenosine’s role in tissue protection may involve mechanisms such as increasing 
the tissue blood flow and protecting against ischemic damage (37). Adenosine is well 
known to play a vasoregulatory role in human coronary arteries (16-17, 62-63). We and 
others have previously also demonstrated the pivotal role for A2AAR in CF regulation (5, 
63, 67, 69). We also have preliminary data showing the involvement of A2AR in 
coronary reactive hyperemia that indirectly supports a physiological role for adenosine in 
CF regulation (data not shown) which is in support of previous in vivo and ex vivo 
reactive hyperemia studies (5, 12, 77). Additionally, it is suggested that A2AAR activation 
contributes to basal tone in coronary circulation through the release of nitric oxide (69). 
Our present data (Figure 5A) also support such a role for A2AAR since SCH58261 
(A2AAR selective antagonist) significantly reduced the baseline CF.   
Due to its low affinity for adenosine, A2BAR is known to be activated in 
conditions where a significant increase in adenosine levels is observed, such as in 
ischemic conditions (25). Therefore, A2BAR may be more involved in pathophysiological 
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conditions rather than physiological situations. However, cardiovascular effects of 
A2BAR and its role in coronary vasodilation still remain to be fully elucidated. It was 
reported that A2BAR plays a role in ischemia/reperfusion and preconditioning (15). 
Additionally, previous studies have used indirect measures such as non-selective 
agonist/antagonist (alloxazine), which is only about 10 fold more selective towards 
A2BAR relative to A2AAR (8), or A2AKO mice (without the use of A2B knockout) to 
indirectly study the role of A2BAR in CF regulation (48, 67). In this study, we 
demonstrated the contribution of both A2A and A2BARs in coronary artery vasodilation 
where we further clarified the individual role of A2BAR with the use of selective A2BAR 
agonist BAY 60-6583 and A2BKO mice (Figure 1). We also demonstrated that A2A and 
A2BARs, out of all ARs, are involved in inducing coronary artery vasodilation with the 
use of A2A/2BDKO mice (Figure 6). Reports suggesting that A1 and A3ARs negatively 
modulate the role of A2A and A2BARs in CF regulation (66, 68) and the presence of only 
A2A and A2BARs on human and porcine coronary endothelial cells (53) may also 
indirectly support their involvement in coronary artery vasodilation. 
Azakura et. al. suggested that the impairment of adenosine-related signaling 
contributes to the pathophysiology of congestive heart failure (2). In addition, we have 
previously demonstrated that A2AAR is up-regulated in high-salt compared to normal-salt 
fed mice (51) and failure to up-regulate A2AAR-induced pathway contributes to the 
development of hypertension (44). Furthermore, few studies have shown that A2BAR is 
selectively up-regulated in ischemic mouse hearts and by hypoxic conditions (3, 18) and 
differential expression of ARs contributes to functional heterogeneity of human 
endothelial cells (21). We have recently shown the up-regulation of A2BAR in A2AKO 
mice (69) and in this current study we demonstrated the up-regulation of A2AAR in 
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A2BKO mice (Figures 2-5), suggesting the presence of a relationship between these two 
ARs. Therefore, further understanding of the relationship between A2A and A2BARs may 
help us towards development of newer therapeutic approaches. Also, the observation that 
the down-regulation/deletion of A2A or A2BAR leads to compensatory up-regulation of 
A2B and A2AAR, respectively, itself supports an important regulatory function for each of 
these AR subtypes.  It is interesting to mention that this trend is observed in hypoxia of 
human umbilical vein endothelial and bronchial smooth muscle cells where hypoxia 
modulates the expression of ARs by decreasing A2AAR mRNA but increasing A2BAR 
mRNA levels (22). It is also noteworthy to mention that adenosine acts as a feed-back 
mediator in heart during hypertrophy and hypoxia (34) during which conditions other 
studies have shown the modification of ARs’ expression (2-3, 18, 22). These kinds of 
interactions have also been observed between other receptor subtypes such as 
adrenoceptors (ADR), where α1ADR compensates for the down-regulation of βADR in 
pathological conditions such as cardiac remodeling (75). 
Adenosine and its agonist are currently being used in clinical settings; The 
vasoregulatory properties of ARs are used clinically in humans for the diagnosis of 
coronary artery disease through the use of Adenosine (Adenoscan) as a substitute for 
exercise stress testing in myocardial perfusion imaging (7). The use of Adenoscan has its 
own limitations due to it blocking the AV conduction (due to activation of A1AR (4, 7)) 
and inducing bronchospasm (probably due to activation of A1, A3 or A2BARs (24, 59)). 
However, these side effects may be alleviated by the development of more A2AR subtype 
selective agonists. A new A2AAR selective agonist called Regadenoson (Lexiscan®) has 
been developed and approved by FDA which is being used clinically in myocardial 
perfusion imaging. During this use of adenosine and its agonist in determining coronary 
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reserve, the assessment of the true maximal dilatation of coronary arteries is an important 
factor (34). However, it is reported that maximal dilatation of coronary arteries with 
vasodilators such as adenosine does not eliminate all coronary vasomotor tone and that 
the role of hemodynamic changes should also be considered (34, 73). Nevertheless, the 
knowledge of the presence of a compensatory interaction between A2A and A2BARs may 
be helpful since most cardiac imagings are done in patients with vascular disease where 
the AR expression may have been already modified due to the disease condition. 
Furthermore, adenosine is being investigated as a treatment during percutaneous coronary 
intervention in order to reduce the myocardial reperfusion injury in patients with 
myocardial infarction (which is usually associated with worsening of cardiac injury and 
function). In these patients, intracoronary injection of adenosine is followed by a better 
myocardial salvage and thus prevention of left ventricular remodeling, ejection fraction, 
decreased infarct size, and ST-segment elevation resolution (10, 26, 46). However, 
Desmet et. al. demonstrated that adenosine significantly ameliorates ST-segment 
resolution while it does not improve myocardial salvage or coronary blood flow (11). 
Additionally, in another study, Ross et. al. showed a relationship between infarct size and 
primary clinical end point (death or heart failure) where adenosine significantly reduced 
the infarct size while, it did not improve the clinical outcome (61).   
It is well known that arterioles, compared to coronary conduit arteries, are the 
major players in flow regulation and as previously reported, A2AAR may be the major 
coronary artery vasodilator compared to A2BAR. Furthermore, large coronary arterioles 
were shown to be less responsive to adenosine than small ones and Hein et. al. have 
reported that mainly A2AARs are expressed in coronary arterioles (32, 42). The same 
disparity of receptor subtype distribution has also been seen with adrenoceptors, with 
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adrenergic constriction of large arterioles being mediated by α1 while in terminal 
arterioles α2 exert this function (56). Additionally, in coronary arterioles, a greater α2 
response has been shown compared to larger coronary arteries (70). Thus, showing the 
up-regulation of A2AAR in A2BKO mice would most likely not be reflected on larger 
coronary conduit arteries such as LAD. Isolation of mouse LAD and other large coronary 
conduit arteries is technically difficult but possible, however isolation of coronary 
resistance arterioles from mouse heart is almost impossible and to our knowledge no one 
has been able to isolate coronary arterioles so far which is a limitation in our study. 
However, A2AAR protein expression in mouse mesenteric artery resistance vessels (up to 
third branch of arterioles) shows the up-regulation of A2AAR in A2BKO mice which 
confirms the compensatory up-regulation of A2AAR in A2BKO mice resistance vessels 
(Figure 3).  
The occurrence of the up-regulatory mechanism phenomenon in our studies may 
be TNF-α-induced and post-transcriptionally regulated (41) or due to DNA methylation 
since this may regulate AR cell surface expression levels (9). Furthermore, HIF-1 has 
also been suggested to up-regulate the expression of A2BAR in hypoxic conditions (76). 
Although, the underlying mechanism may not be understood at this time, it seems that 
this relationship only exists between A2A and A2BARs and not between A1 or A3ARs 
since there was no significant difference between the concentration response curve for 
CCPA (A1AR selective agonist) and Cl-IBMECA (A3AR selective agonist) in 
A2A/2BDKO mice compared to WT (data not shown). 
Potassium channels have been suggested to be involved in regulating blood flow 
and blood pressure and in AR signaling pathways (29, 49, 78). For example, inward 
rectifier K
+
 (KIR) channels may play a role since their presence has been reported on 
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coronary artery smooth muscle cells (CASMCs) (54, 60, 65), in addition, to their role as 
the dominant K
+
 conductance in resting membrane potential (38). Moreover, adenosine is 
reported to activate ATP-sensitive potassium (KATP) channels in rabbit mesenteric 
arteries and isolated CASMCs (58, 65). Others have demonstrated the presence of KATP 
channels on coronary arteries and CASMCs (28, 65) and their role in A2A-induced effect 
in reactive hyperemia and retinal microvessels dilation (5, 33, 77). However there are no 
reports to our knowledge suggesting the involvement of KATP channels in A2A and 
A2BARs-induced changes in mouse CF.  
In this study, we used mitochondrial KATP channel blocker, 5-hydroxydeconoate 
(5-HD) and glibenclamide to test KATP channels involvement in A2A and A2BARs-induced 
CF changes. Glibenclamide blocked the NECA-induced increase in CF in A2A and 
A2BKO and BAY60-6583-, and CGS21680-induced increase in CF in WT mice. 
However, 5-HD had no effect on NECA-induced increase in CF, which may suggest a 
role for non-mitochondrial KATP channels in both A2A and A2BARs signaling pathways 
(Figures 7-9A). However, this study does not show if the KATP channels are located on 
endothelial or SMCs. This is important since endothelial dysfunction is an early risk 
factor for cardiovascular diseases where a reduced adenosine response has been reported 
(19). Further, Wang et. al. suggested that activation of endothelial KATP channels might 
result in the protection against endothelial dysfunction (74). We think that adenosine-
induced activation of KATP channels may be indirectly through release of some other 
mediators such as hydrogen peroxide (27), which was previously suggested to be the 
endothelium-derived hyperpolarizing factor (47) and that may be involved in 
cardiovascular dysfunction (64). Elucidations of these signaling pathways will help us 
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better understand the underlying cause of reduced adenosine response in cardiovascular 
diseases. 
The availability of gene deleted knockout mice has been an important tool to 
dissect the physiological and pharmacological pathways for elucidating the role of a 
single receptor. However, in some instances, mice lacking a specific receptor gene 
exhibit phenotypic differences such as higher blood pressure in A2AKO mice (43).  
Therefore, in this study we used both pharmacological and molecular (single and double 
gene knockout) approaches to confirm our results. We also evaluated the baseline 
parameters of WT and KO hearts (Table 1). The baseline LVDP of A2A/2BDKO was 
significantly higher compared to WT, which may be attributed to alterations at second 
messenger or translational levels. The relationship between A2A and A2BARs and 
activation of other signaling pathways such as an increase in the levels of cAMP and Ca
2+
 
may compensate for the deletion of A2A/2BARs (35, 37). Even adrenoceptors may 
compensate for the absence of A2A and A2BARs since there are reports showing direct and 
indirect anti β-adrenergic effect of adenosine, suggesting the presence of an interaction 
between these two different GPCRs (49). Further experiments are required to better 
understand the relationship between these two receptor classes. There are no significant 
differences in baseline HR, LVDP, and CF of A2AKO and A2BKO mice compared to WT. 
We also tested the A2BKO mice for endothelium functionality using bradykinin where we 
found no significant difference between the A2BKO and WT groups, thus, showing the 
presence of a normal functional endothelium in A2BKO (data not shown).  
CGS21680 and NECA induced an increase in LVDP of WT and A2BKO but not 
A2A/2BDKO. BAY60-6583 also induced an increase in LVDP of WT mice. These data 
support our previous report that A2A and A2BARs may be involved in cardiac contractility 
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and positive inotropic effect (Figures 1, 2, and 4C) (69). Changes in CF can affect the 
contractility (Gregg effect) which is an inherent problem with the isolated perfused heart 
preparation. However, as shown in this study (Figures 2 and 6), the increase in CF comes 
earlier than the changes in LVDP which may suggest that the observed effects of A2ARs 
activation on LVDP may not be due to Gregg’s effect. The opening of KATP channels 
may also affect the contractility independent of CF changes which may be independent of 
non-mitochondrial KATP channels in this study since there is no difference observed in 
NECA-induced changes in LVDP in the presence of 5-HD (mitochondrial KATP channel 
blocker) while a significant decrease in NECA-induced changes in LVDP was shown in 
the presence of glibenclamide (non-selective KATP channel blocker) (Figure 7). 
Additional studies are needed to define the role of A2ARs on LVDP. However, our data 
from A2A/2BDKO are very important since they show that only A2A and A2BARs are 
involved in LVDP and coronary vasodilation which could be further exploited for 
therapeutic approaches such as heart failure.  
Our current study also confirms our previous finding that A1AR plays a role in 
HR (68) while A2A and A2BARs do not since BAY60-6583 (Figure 1B) and CGS21680 
(Figure 4B) did not affect HR while NECA (non-selective agonist) decreased the HR 
(Figure 2B). Additionally, our data showed a decrease in baseline HR in the presence of 
glibenclamide (Figures 7 and 9B) which could be due to the presence of KATP channels 
on atria and ventricle (79) and the KATP channel-dependent potassium efflux-induced 
shortening of cardiac action potentials and hence a decrease in HR (79).  
In conclusion, we showed for the first time, the individual role of A2BAR and the 
contribution of A2AAR in A2ARs-mediated coronary vasodilation using A2BKO and 
A2A/2BDKO mice along with the use of A2BAR and A2AAR selective agonists. We found 
86 
 
that A2A and A2BARs contribute to coronary artery vasodilation which involves KATP 
channels and that A2AAR is up-regulated in A2BKO mice. These findings are another step 
toward a better understanding of ARs’ pharmacology in coronary artery and the 
heterogeneity of CF responses by ARs which may lead to better therapeutic approaches 
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Interactions between A2A adenosine receptor, hydrogen peroxide, and K
+
-ATP 





Myocardial metabolites such as adenosine mediate reactive hyperemia (RH), partially, by 
activating ATP-dependent K
+
 (KATP) channels in coronary smooth muscle. In this study, we 
investigated the role of A2 adenosine receptors (ARs) and their downstream signaling 
mechanisms in RH. We tested the hypothesis that coronary RH involves A2AARs, hydrogen 
peroxide (H2O2), and KATP channels using A2A and A2B single (KO) and A2A/2B double knockout 
(DKO) mice hearts in a Langendorff heart. Flow debt-to-repayment ratio (RPA//DA) following a 
15s occlusion was 1.3±0.1 in WT which was reduced in hearts from A2AKO (0.9±0.1), but not 
A2BKO (1.2±0.1) mice. Catalase (1250 U/ml), an enzyme that breaks down H2O2, significantly 
reduced the baseline flow (ml/min/g) in A2AKO hearts (16.8±0.9) compared with control 
(19.4±1.6) and WT in the presence and absence of catalase (21.4±2.1 and 19.8±0.9, respectively). 
However, catalase significantly reduced the RPA/DA in WT (0.8±0.1) but, not in A2AKO 
(0.9±0.1) mice compared with its control. Patch clamp experiments demonstrated that adenosine 
(10μM) activated a glibenclamide (10μM; a KATP channel blocker)-sensitive conductance (nS/pF) 
in smooth muscle cells from WT (0.048±0.01) but not A2A/A2BDKO (0.016±0.01) mice. 
Importantly, however, conductance activated by pinacidil (10 μM; a KATP channel opener) was 
similar in cells from WT and A2A/A2BDKO mice (0.013±0.034 vs. 0.012±0.04 nS/pF). 
Additionally, in WT smooth muscle cells, H2O2 (1 mmol/L) activated a glibenclamide-sensitive 
conductance (0.074±0.02 nS/pF). Our data indicate that A2AARs are coupled to KATP channels in 
RH, in part, via the production of H2O2 as a signaling intermediate. 
 
Keywords: coronary circulation, ischemic vasodilation, adenosine receptors, knockout mice, 







The heart responds to acute ischemia by transiently increasing blood flow in a 
phenomenon called reactive hyperemia (RH) (7). The temporary reduction in coronary vascular 
resistance is mediated by chemical signals released into blood (47), including adenosine (44). 
Adenosine induces its effects through activation of its receptors (AR) namely A1, A2A, A2B, and 
A3. Adenosine’s cardiovascular effects depend on the activation of the subtype of receptor 
involved, where A2ARs are known to play a role in coronary vasodilation through their action on 
both endothelial and smooth muscle cells. Our laboratory and others have shown that A2AARs 
play a pivotal role in the regulation of coronary flow (CF) (48, 50), while, A2BARs are also 
involved, albeit with a lesser contribution compared to A2AARs (32, 48, 50). Additionally, 
pharmacological studies indicate that A2A and A2BARs are the subtypes most likely involved in 
coronary RH (2, 11, 62). However, undesirable overlap in the pharmacological profiles of 
adenosine receptor antagonists obfuscates the relative contribution of A2A and A2BARs in RH. 
Thus, in order to more specifically determine the roles of A2A and A2BARs in coronary RH, we 
used Langendorff-perfused hearts from wild type (WT) and A2A, A2B knockout (KO) and A2A and 
A2B double knockout (DKO) mice. 
 Numerous mediators and end effectors of coronary RH have been proposed. Importantly, 
however, information remains scarce regarding the role of H2O2, a coronary metabolic and 
endothelium-dependent vasodilator (29, 45, 58), and its interactions with ARs and KATP channels. 
Some support for H2O2 in RH has been provided by studies of skeletal muscle and isolated 
coronary arterioles (3, 20). The idea that KATP channels participate in coronary RH is well 
established (1, 12), but it is unknown whether H2O2 couples adenosine receptor activation to KATP 
channel activity. KATP channels are known to mediate, at least in part, H2O2-induced dilatation of 
arterioles from skeletal muscle and brain (25, 55) and cardiac myocytes (18). However, to our 
knowledge, direct evidence of this mechanism in smooth muscle is still to be elucidated. Thus, we 
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ascertained whether H2O2 is involved in coronary RH and whether H2O2 mediates the coupling of 
adenosine receptors to activation of KATP in coronary RH. 
  
Materials and Methods 
Animals. An Institutional Animal Care and Use Committee at West Virginia University 
School of Medicine approved all experimental protocols. We followed guidelines set forth by the 
American Physiological Society and National Institutes of Health regarding the care and use of 
laboratory animals. A2A and A2B knockout mice, both backcrossed 12 generations to the WT 
C57BL/6 background (Jackson Laboratory; Bar Harbor, ME), were bred to generate A2A/A2B 
double heterozygotes. Double heterozygotes were intercrossed, 1/16 of the offspring were 
A2A/A2B double knockouts, and A2A/A2B knockout breeding pairs were established. Mice were 
caged in a 12:12-hr light-dark cycle with free access to standard chow and water. 
WT, A2A, and A2BKO and A2A/2BDKO mice. WT mice of a mixed C57/BL6 genetic 
background were purchased from The Jackson Laboratory (Bar Harbor, Maine). All four WT, 
A2AKO, A2BKO, and A2A/2BDKO strains were bred at the West Virginia University animal facility 
as a sub-colony of the original strain. All animal care and experimentation were in accordance 
with the West Virginia University Institutional Animal Care and Use Committee and the 
principles of the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals.” 
Langendorff-perfusion. Mice (10-14 wks of age) were anesthetized with sodium 
pentobarbital (50 mg/kg i.p.) and hearts were excised into heparinized (5 U/ml) ice-cold Krebs-
Henseleit (KH) buffer. KH contained (mmol/L) 119 NaCl, 11 glucose, 22 NaHCO3, 4.7 KCl, 1.2 
KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2 pyruvate and 0.5 EDTA. Hearts beat spontaneously when 
retrogradely perfused (80 mmHg) with 37°C KH bubbled with 95% O2 and 5% CO2. The left 
atrium was removed and the left ventricle drained. A fluid-filled balloon was inserted into the left 
ventricle and connected to a transducer for pressure measurements. Left ventricular diastolic 
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pressure was adjusted to 2-5 mmHg. Coronary flow was measured with a probe (Transonic 
Systems; Ithaca, NY) in the aortic perfusion line. Hearts were paced to 400 beats/min and 
function allowed to stabilize. Hearts with persistent arrhythmias or developed pressure less than 
80 mmHg were excluded from the study. Baseline coronary flow and cardiac function were 
measured using a Power Lab data acquisition system (AD Instruments; Colorado Springs, CO). 
Hearts were then subjected to 15 seconds of total flow occlusion to elicit hyperemia. Catalase 
(Sigma Chemical Co.; St. Louis, MO) was delivered into the aortic perfusion line using a 
microinjection pump (Harvard Apparatus; Holliston, MA) as 1% of coronary flow to achieve a 
final concentration of 1250 U/ml (57, 60). 
 
Patch clamp. Single smooth muscle cells were enzymatically isolated from the aortas of 
WT and A2A/A2B knockout mice. For cell isolation, a simple HEPES-buffered saline was used and 
contained (mmol/L) 135 NaCl, 5 KCl, 1 MgCl2, 0.36 CaCl2, 10 glucose, 10 HEPES, and 5 Tris; 
pH 7.4. The aorta was placed in this solution plus (mg/ml) 2 collagenase, 1 elastase, 2 bovine 
serum albumin, and 1 soybean trypsin inhibitor for 15 min at 37°C. The tissue was passed 
through the tip of a fire-polished Pasteur pipette to liberate single cells. Smooth muscle cells were 
pelleted at 0.5 g, resuspended in enzyme-free buffer, placed on ice, and used within 8 hr. Cells 
were placed in a recording chamber atop an inverted microscope and perfused with a HEPES-
buffered solution (as above) containing 140 mmol/L K
+
. Patch pipettes (3-5 MOhms) were filled 
with this 140 mmol/L K
+
 solution supplemented with 5 mmol/L Mg-ATP and 0.1 mM Na-GTP; 
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pH 7.1. Inward KATP currents were recorded in the conventional whole-cell mode (with Nernst 
equilibrium potential for K
+
 set to 0 mV). The membrane potential was held at -80 and ramped or 
stepped to potentials between -100 and +100 mV. Currents were low-pass filtered a 1 kHz and 
digitized at 5 kHz. Series resistance and whole-cell capacitance were compensated as completely 
as possible using circuitry of the amplifier (PC-505, Warner Instruments; Hamden, CT). This 
amplifier was interfaced to a computer with pClamp 9 software for data acquisition and analysis 
(Molecular Devices; Sunnyvale, CA). 
Statistical analysis. Statistical analyses were made with t-test and one- or two-way 
analysis of variance (ANOVA) with post hoc tests as indicated. Results were considered 
significant when P < 0.05. Values are means ± SEM from n number of animals. 
 
Results 
Involvement of A2AARs in coronary reactive hyperemia. We used WT and A2AKO mice in 
order to test the involvement of A2AARs in coronary RH. The flow debt-to-repayment ratio was 
significantly reduced in A2AKO (0.9±0.1, n=8) compared with WT (1.3±0.1, n=6) mice (Figure 
1B) while, the peak flow was not different between the two groups (WT: 42.7±2 ml/min/g, n=6 
vs. A2A KO: 42.9±1.7 ml/min/g, n=8, Figure 1C). The resting flow of 19.4± 1.6 ml/min/g (n=8) in 
A2AKO was similar to WT (19.8 ± 0.9 ml/min/g, n=6, Table 1).  
A2BARs may not be involved in coronary reactive hyperemia. In order to characterize the 
role of A2BARs in coronary RH, we performed our RH experiments in WT and A2BKO mice. The 
flow debt-to-repayment ratio (Figure 2B) and peak flow (Figure 2C) in A2BKO, 1.2±0.1 and 
44.2±0.5 ml/min/g (n=4), respectively, were not different compared with WT, 1.3±0.1 and 42.7±2 
ml/min/g (n=6), respectively. Additionally, the resting flow of A2BKO, 20.3±1.1 ml/min/g was 
not different compared with WT, 19.8±0.9 ml/min/g, respectively (Table 1). 
Involvement of only A2ARs in coronary reactive hyperemia. Since we have previously 
shown that only A2A and A2BARs, out of four ARs, are involved in the regulation of CF (48), we 
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tested the involvement of other ARs than A2ARs in coronary RH using WT and A2A/2BDKO mice. 
The flow debt-to-repayment ratio was significantly higher in WT (1.3±0.1, n=6) compared with 
A2A/2BDKO (1±0.1, n=8) mice (Figure 3B), which may be only due to the absence of A2AARs, 
nevertheless, the peak flow was not different between the two groups, 42.7±2 ml/min/g and 
41.6±1.2 ml/min/g, respectively (Figure 3C). Additionally, the resting flow of A2A/2BDKO, 
18.6±0.6 ml/min/g (n=8) was not different compared with WT (Table 1). 
Adenosine activates KATP channels. It is known that KATP channels play a role in coronary 
RH (2, 62). We have also previously reported that both A2A and A2B ARs induce coronary 
vasodilation, and hence an increase in CF, through activation of KATP channels (48). We 
established this finding by using our isolated heart system (48). However, in this study we wanted 
to investigate this finding on a molecular level using patch clamp. Since both A2A and A2B ARs 
were shown to activate KATP channels, in this study, we used A2A/2BDKO mice in order to be able 
to distinguish the currents activated due to activation of ARs. Adenosine (10μmol/L) activated a 
conductance (nS/pF) sensitive to the KATP channel blocker, glibenclamide (10μmol/L), in smooth 
muscle cells from WT (0.048±0.01) but not A2A/A2BDKO (0.016±0.007) mice. Also, pinacidil (10 
μmol/L; a KATP channel opener) activated the same conductance similarly in cells from both WT 
and A2A/A2BDKO mice (0.013±0.034 vs. 0.012±0.04 nS/pF) (Figure 4). 
Involvement of H2O2 in adenosine-induced increase in coronary flow. To test if H2O2 
induces coronary vasodilation, we performed exogenous H2O2 concentration-curve. Exogenous 
H2O2 significantly increased the coronary flow from baseline (from 11.3 to 38.1 ml/min/g, data 
not shown). We used catalase (1250 u/ml), an enzyme which breaks down hydrogen peroxide into 
water and oxygen, to test its effect on adenosine-induced increase in CF in WT mice. Catalase 
significantly decreased adenosine-induced increase in CF in WT (from 30 ± 4.4 to 8.4 ± 1 
ml/min.g, n=4), A2AKO (from 33.2 ± 2.3 to 9.9 ± 1 ml/min/g, n=4), and A2BKO (from 35.2 ± 1.5 
to 13.4 ± 0.8 ml/min/g, n=4) mice (Figure 5A). Catalase also significantly decreased adenosine-
induced changes in LVDP in WT (from 122.4 ± 11 to 78 ± 7 mmHg), A2AKO (from 119.2 ± 4.1 
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to 74.6 ± 4 mmHg), and A2BKO (from 139.1 ± 6 to 81 ± 10.1 mmHg) mice while it had no effect 
on HR (Figures 5 B-C). 
Involvement of H2O2 in coronary reactive hyperemia. Since we showed that adenosine is 
involved in coronary RH and that it induces coronary vasodilation through release of H2O2, we 
wanted to test if H2O2 itself is also involved in coronary RH. Therefore, we used catalase (1250 
u/ml) in WT mice. Catalase significantly decreased the flow debt-to-repayment ratio in WT 
compared with its control, 0.8±0.1 (n=6) vs. 1.3±0.1 (n=6), respectively (Figure 6B). However, 
the resting flow was similar to WT in the presence of catalase (21.4±2.1 ml/min/g, n=6) 
compared to its control (19.8±0.9 ml/min/g, n=6) (Table 1). Nevertheless, the peak flow in WT 
mice, in the presence of catalase, (38.6±2.4 ml/min/g, n=6) was also significantly attenuated 
compared to its control (42.7±2 ml/min/g, n=6) (Figure 6C). 
Involvement of H2O2 in A2AR-mediatesd coronary reactive hyperemia. We used catalase 
(1250 u/ml) in A2AKO mice in order to investigate the role of H2O2 in A2AAR-induced effects in 
coronary RH. Catalase significantly decreased the flow debt-to-repayment ratio in A2AKO 
(0.9±0.1, n=6) (Figure 7B) compared with WT in the absence of catalase (1.3±0.1, n=5) (Figures 
1,2,3, and 6 B) while, it was not different compared to WT (0.8±0.1, n=6) in the presence of 
catalase. Also, there was no difference between flow debt-to-repayment ratio in A2AKO in 
presence of catalase (0.9±0.1, n=6) compared with A2AKO (0.9±0.1, n=8) (Figures 7B). Further 
resting flow of A2AKO in the presence of catalase (16.8±0.9 ml/min/g) was significantly lower 
compared with WT (19.8±0.9 ml/min/g) and A2AKO (19.4±1.6 ml/min/g) in the absence of 
catalase, while there was no difference between the two latter groups (Table 1). The peak flow in 
A2AKO, in the presence of catalase, (36.3±1.4 ml/min/g, n=6) (Figure 7C) was significantly lower 
compared with WT (42.7±2 ml/min/g, n=6) (Figure 1C) and A2AKO (42.9±1.7 ml/min/g, n=8) in 
the absence of catalase (Figure 7C); this is when the WT and A2AKO peak flow, in the presence 
of catalase, were similar (Figure 1C). These findings may suggest that A2AARs may, at least in 
part, play their role in coronary RH through release of H2O2.  
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H2O2 activates KATP channels. In smooth muscle cells from WT mice, H2O2 (1 mmol/L) 

























Fig. 4.1 Repayment volume (B), but not resting flow (A) or peak flow (C), is reduced in 
A2AKO (n=8) mice, compared with WT (n=6), in coronary RH. *Significant difference 
compared with WT, p<0.05. 











































































Fig. 4.2 Baseline coronary flow (A), peak flow (B), and flow repayment area (C) of 
coronary RH are normal in A2BKO (n=4) mice compared with WT (n=6). 









































































Fig. 4.3 Changes on coronary flow (A), peak flow (B), and flow repayment area (C) in WT 
(n=6) and A2A/2BDKO (n=8) mice during coronary RH. *Significant difference compared 
with WT, p<0.05. 











































































Fig. 4.4 Adenosine-induced KATP current is reduced in smooth muscle cells of A2A/2BDKO 
mice.  (A) Glibenclamide-sensitive conductance (nS/pF) in WT and A2A/2BDKO mice. (B) 
Group data showing reduced effect of adenosine in A2A/2BDKO mice (n=4), but response to 


































































































Fig. 4.5 Attenuated adenosine-induced increase in coronary flow (A) and LVDP (C), and 
normal heart rate (B), in WT (n=4), A2AKO (n=4), and A2BKO (n=4) mice, in the presence of 
catalase (Cat). *Significant difference compared to corresponding control, p<0.05. 








































































Fig. 4.6 Attenuated peak flow (B) and Repayment area (C), but normal baseline CF (A), in 
the presence of catalase (Cat) in WT (n=6) mice. *Significant difference compared with WT, 
p<0.05. 












































































Fig. 4.7 Reactive hyperemia-induced changes on coronary flow (A), peak flow (B), and flow 
repayment area (C) in the presence (n=6) and absence (n=8) of catalase (Cat) in A2AKO 
mice. 











































































Fig. 4.8 H2O2 increases a glibenclamide-sensitive conductance (nS/pF) in WT smooth 
muscle cells. (A) Representative trace showing effect of H2O2 to increase KATP current. (B) 
Group data (n=5 mice) illustrate effect of H2O2 relative to pinacidil. *Significant difference 
compared with control, p<0.05. 
 

































































Fig. 4.9 Effect of catalase on adenosine and pinacidil mediated increase in 






























































Resting flow, debt area (DA), peak flow, flow repayment area (RPA), and debt to repayment area 






   
Debt Area 












WT 19.8±0.9  4.9±0.2  42.7±2  6.3±0.4  1.3±0.1  
A2AKO 19.4±1.6  4.9±0.4  42.9±1.7  4.5±0.2*  0.9±0.1*  
A2BKO  20.3±1.1  5.1±0.3  44.2±0.5  6.1±0.1  1.2±0.1  
A2A/2BKO  18.6±0.6  4.7±0.1  41.6±1.2  4.9±0.2*  1±0.1*  
WT+Cat  21.4±2.1  5.3±0.5  38.6±2.4*  4.4±0.4*  0.8±0.1*  
A2AKO+Cat  16.8±0.9*  4.2±0.2*  36.3±1.4*  4.1±0.4*  0.9±0.1*  
















The new findings in this study show: 1) a better elucidation of the individual involvement 
of A2AARs in RH, 2) a demonstration that H2O2 contributes to CF responses in RH, and 3) that 
H2O2 couples adenosine-mediated CF responses in RH to KATP channel activation. Using A2A and 
A2BKO and A2A/2BDKO mice, we showed that only A2AAR, out of four AR subtypes, is involved 
in RH. Additionally, we showed for the first time the involvement of H2O2 in mouse coronary RH 
in addition to its involvement in A2AAR-induced KATP channel activation.  
Increased oxygen demand over oxygen supply ratio of the myocardium is exerted through 
myocardial oxygen tension (pO2), which is decreased in ischemic conditions. This fall in pO2 
leads to the breakdown of adenine nucleotides leading to the production of adenosine that is 
known to mediate local metabolic control of CF (14). Previous RH studies investigating the effect 
of different occlusion periods suggested that metabolic vasodilatory factors are the primary 
mediators responsible for the increase in flow during RH (7, 17, 38, 39). Further, our laboratory 
and others have previously shown that activation of A2A and A2B ARs induces an increase in CF 
(37, 46, 49). Therefore, in this study, we wanted to test the role of adenosine, a well established 
local metabolite, in CF changes in RH. The involvement of adenosine in coronary RH was 
recently reported in an in vivo dog study, where the AR subtypes involved was not assessed (11). 
Nevertheless, using an A2AAR selective antagonist (SCH58261), Zatta et al. reported coronary 
RH responses mediated by A2AARs with a flow repayment area decrease of up to 30% and no 
change in peak flow (62). Also, in a previous in vivo study in dogs, the role of A2BAR-mediated 
CF changes in RH was assessed using a non-selective antagonist (alloxazine) which is only about 
10 fold more selective towards A2BARs relative to A2AARs (2). Therefore, a further study was 
needed in order to fully elucidate the role of ARs in coronary RH without the effect of 
pharmacological changes. The availability of gene deleted knockout mice has been an important 
tool to analyze the physiological and pharmacological pathways for elucidating the role of a 
single receptor. Therefore, in this study, using A2A and A2BKO isolated mice hearts, we directly 
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showed that A2AARs contribute to CF changes in mouse coronary RH by demonstrating a 
significant decrease in flow repayment time and volume (flow repayment area) in A2AKO mice 
compared with WT. These results are in accordance with recent studies showing a role for ARs in 
flow repayment area and not the peak flow (62). However, our results from A2BKO and 
A2A/2BDKO mice did not suggest any role for A2BARs in CF changes in RH. Due to its low 
affinity for adenosine, A2BARs are suggested to be activated in conditions where a significant 
increase in adenosine levels is observed (15). For example it was reported that A2BARs play a role 
in ischemia/reperfusion and preconditioning (13). Therefore, A2BARs may be more involved in 
severe ischemic pathophysiological conditions such as stroke or in protective preconditioning 
pathways rather than in physiological situations. Indeed, A2ARs agonists are being investigated as 
a treatment during percutaneous coronary intervention for the reduction of myocardial 
reperfusion injury in patients with myocardial infarction, which is well established to be 
associated with worsening of cardiac injury and function (6, 10). 
Berne’s adenosine hypothesis suggests that increase in myocardial oxygen consumption 
decreases the myocardial oxygen tension which leads to the release of adenosine from 
cardiomyocyte (53), where A2AARs have also been found to be expressed in both human and 
mouse (4, 24). Furthermore, a role for H2O2 in metabolic vasodilation is already established (59). 
Chilian et al. suggested that H2O2 production increases in proportion to cardiac metabolism in 
order to couple the coronary blood flow to myocardial oxygen tension (45). It is interesting to 
know that both H2O2 and adenosine are released from cardiomyocytes through which they 
modulate vascular tone (19). Nevertheless, it is also well recognized that hemodynamic changes-
induced release of mediators are also involved in RH; a sudden increase in flow after reperfusion 
activates shear stress-sensitive mechanisms (21, 41, 52, 61), illustrating the release of 
endothelium-dependent derived factors that may limit myogenic constriction and, therefore, 
modifying the RH time or flow repayment area. In fact, recent reports have established the 
contribution of H2O2 in flow-induced dilation of isolated human coronary arteries (29) and in 
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reactive dilation of rat isolated coronary arterioles (20). Therefore, in this study, as EDHF in 
humans and mice (26, 27, 58), we also investigated the role of H2O2 in CF changes during 
coronary RH using isolated heart (compared with isolated vessels). Additionally, due to the 
involvement of both adenosine and H2O2 as metabolic factors regulating CF, in this study, we 
also tested the involvement of H2O2 in AR-induced effect in CF regulation and RH. We showed 
for the first time that in the presence of catalase, which breaks down H2O2 into water and oxygen, 
adenosine-induced increase in CF is abolished in WT, A2AKO (where A2BAR is the only AR 
mediating vasodilation), and A2BKO (where A2AAR is the only AR mediating vasodilation) 
(Figure 5), showing that H2O2 plays a role in A2AR-mediated signaling pathway when inducing 
an increase in CF. In this study, we also showed for the first time that the RH repayment time and 
volume (flow repayment area) in addition to flow debt-to-repayment ratio were significantly 
decreased in WT isolated mice hearts in the presence of catalase, showing the contribution and 
release of H2O2 during coronary RH. Furthermore, since catalase decreased the flow debt-to-
repayment ratio in both A2AKO and WT mice with no difference compared to each other and 
compared to A2AKO in the absence of catalase, we suggest that H2O2 released during coronary 
RH is, at least partly, mediated through activation of A2AARs. Showing that catalase significantly 
decreased peak flow in WT and A2AKO mice (while peak flow of A2AKO was not different 
compared with WT mice in the absence of catalase), may further signify that H2O2 may also be 
released through activation of other pathways. Nevertheless, using patch clamp studies, we 
showed that H2O2 increases glibenclamide (KATP channels blocker) sensitive currents. Putting 
together these findings with our previous and current results, showing that adenosine activates 
KATP channels by means of its A2ARs, we are suggesting that, at least partly, H2O2 couples the 
activation of ARs to KATP channels during coronary RH. Nevertheless, further in vivo and in vitro 
studies are needed to fully elucidate the complex mechanisms of action involved in RH. We also 
have to highlight that the magnitude of hyperemia is also determined by the baseline flow. In this 
study, we observed that H2O2 or knocking out of the A2AARs, solely, do not decrease the baseline 
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CF; however, synergistically they significantly decrease the CF baseline, which by itself may 
suggest that there might be a compensatory relationship between A2AARs and H2O2 (Table 1).  
Since, in this study, we used isolated heart, the contribution of flow/shear stress- or 
pressure-dependent coronary mechanisms in the development of RH could not be clearly 
elucidated or isolated from the effect of local metabolic factors. However, an ex vivo isolated 
heart model certainly provides us with more valuable data closer to the physiological in vivo 
responses compared with in vitro isolated vessels, since it reflects the overall end effect of 
shear/pressure stress- and metabolites-induced effects during coronary RH. Additionally, an ex 
vivo study, such as the current study, eliminates the complexity of the role of neuronal and 
hormonal effects and, hence, enabling us to better understand the tissue selective responses and 
mechanisms involved during coronary RH. We also have to mention a second limitation of our 
study that has to do with performing patch clamp experiments on smooth muscle cells from aorta, 
as a model to complement functional studies from the coronary arteries. Perhaps a better 
approach would be to study smooth muscle cells isolated from mouse coronary arteries or 
arterioles. However, to our knowledge, there are no reports using mouse coronary smooth muscle 
in patch clamp setting in order to study ion channel currents due to its own limitations such as 
isolation and experimental procedures required. Therefore, most studies investigating coronary 
ion channels show currents from aorta as a tool (5, 23, 28). Also, KATP channels are known to be 
important regulators of coronary vascular tone in mice (5, 28). Thus, aortic smooth muscle cells 
appear to be an appropriate substitute for coronary smooth muscle cells in this regard.  
The release of H2O2, as endothelium-derived hyperpolarizing factor (EDHF) in mice and 
humans (26, 27), could be induced by various factors. Morikawa et al. suggested that Cu,Zn-SOD 
plays an important role as an EDHF synthase in mice (31). It is also likely that H2O2 is produced 
from superoxide anions from several sources in endothelium, such as eNOS, lipoxygenase, 
cytochrome p-450 enzymes, and NADPH oxidases (27). Further, it is reported that adenosine-
mediated effects are partially endothelium dependent and that adenosine also induces vasodilation 
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through production of cytochrome p-450 metabolites (34, 35), NO (50), and NADPH oxidases 
(data not shown). Therefore, comparing these signaling pathways, one may speculate that 
adenosine-induced release of H2O2 may involve activation of epoxygenases pathway, eNOS, or 
NADPH oxidase. However, further studies are needed to identify these signaling pathways.  
It is known that H2O2 induces vasodilation; however, there are also reports showing that 
H2O2 induces vasoconstriction (8, 16, 30) and that H2O2 inhibits vasodilation to adenosine in 
isolated porcine coronary arteries (51). Nonetheless, it was suggested that the vascular effect of 
H2O2 depends on its concentration (8). To the best of our knowledge there is limited information 
on the endogenous level of H2O2, however, H2O2 levels between 2.5-50 µmol/L have been 
reported in human plasma (9, 22, 54). Exogenous infusion of H2O2, up to 6x10
-6
mol/L (6µmol/L), 
caused a significant increase in CF in isolated mouse heart (data not shown) from which point 
onward (at 10
-5
mol/L ) H2O2 started to induce coronary vasoconstriction which was also 
accompanied by a decrease in left ventricle pressure and +dp/dt (data not shown). It seems that 
endothelial cells are less vulnerable to H2O2 since a relatively high concentration of H2O2 >200 
µmol/L is generally required to produce irreversible endothelial barrier dysfunction (40, 56). 
Therefore, H2O2-induced decrease in CF at 10
-5
mol/L concentration may be due to H2O2-induced 





mol/L. Therefore, the discrepancy between our study and other studies 
regarding H2O2-induced effects may be dependent on the level of H2O2 released. For example, 
Thengchaisri et al. showed that H2O2 in concentrations below 10 µmol/L did not modify NO-
mediated vasodilatory responses. Such variations may also be dependent on the species, vascular 
beds, and experimental models such as ex vivo vs. in vitro. However, overall, we can only 






It is well established that activation of KATP channels plays a major role in coronary RH 
in addition to its contribution to AR-mediated CF changes (2, 48, 62). However, identification of 
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the factor(s) that activates these channels was not assessed in previous studies. Recent studies 
have shown the association of K
+
 ions in H2O2–induced vasodilation (42, 43, 45). These channels 
were also shown to mediate, at least in part, H2O2-induced dilation of arterioles from skeletal 
muscle and brain (25, 55). Further, it has been shown that H2O2 activates KATP channels in 
pancreatic beta cells and cardiac myocytes (18, 33). Nevertheless, direct evidence of this 
mechanism in smooth muscle and the role of adenosine as the inducer of this mechanism is 
lacking. In this study, we showed for the first time that KATP channels on smooth muscle cells are 
activated by H2O2 and, at least partly, adenosine induces the release of H2O2 and, hence, 
activation of KATP channels. It is worth mentioning that A2AR-induced increase in CF is through 
activation of non-mitochondrial KATP channels (48) and, therefore, one can speculate that at least 
the source of H2O2-induced CF changes in RH due to activation of ARs may not be mitochondria 
related. However, further experiments are needed to better understand the role of mitochondrial 
and non-mitochondrial KATP channels in RH coronary flow responses. 
Finally catalase induced a decrease in adenosine-induced increase in LVDP. This 
inhibition may be due to Gregg’s effect since at this concentration adenosine has significantly 
increased both CF and LVDP. The opening of KATP channels may also affect the contractility 
independent of CF changes. It is worth mentioning that adenosine is shown to activate KATP 
channels and that glibenclamide, a KATP channel blocker, is reported to decrease reactive oxygen 
species (36). Nevertheless, further studies are needed to better understand the role of H2O2 in 
LVDP. 
This study is another step in the direction of better understanding of the CF regulation 
and its heterogeneity that may help us towards development of treatments for various clinical uses 
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The work presented in this dissertation confirms the heterogeneity of coronary 
flow responses mediated by activation of adenosine receptors (AR). In this dissertation, 
we established that A2A/B AR subtypes may have differing contributions in the regulation 
of CF under varying conditions.  
We suggested that out of all four AR subtypes, A2AARs and A2BARs induce 
coronary artery (CA) vasodilation, since exogenous adenosine did not induce any 
increase in CF in A2A/2BAR double knockout mice. Additionally, each of these two AR 
subtypes further compensate for the deletion of the other subtype; indeed A2AARs 
expression was up-regulated in A2BKO mice. We established the presence of such 
compensatory mechanism via the use of selective and non-selective agonists and 
antagonists. Furthermore, since some inconsistencies are reported between the results 
obtained from pharmacological and molecular (knockout mice) approaches, we also used 
AR knockout mice to further confirm our findings. The differing expression of A2A/2B 
ARs is reported in many cardiovascular diseases and, therefore, the knowledge of the 
presence of such compensatory mechanisms between A2A and A2B ARs may contribute to 
the future development of new treatment approaches. In fact, A2ARs are being 
investigated as a treatment during percutaneous coronary intervention for the reduction of 
myocardial reperfusion injury in patients with myocardial infarction, which is well 
established to be associated with worsening of cardiac injury and function.  
The next step was to determine the effector, located on SMCs, causing the final 
effect of coronary vasodilation mediated by activation of A2ARs. We not only learned 
that both A2AAR- and A2BAR-mediated CF effects are via activation of non-
mitochondrial KATP channels but, we suggest that, no matter what the A2AR-induced 
coronary vasodilation signaling pathway may be, it may be through activation of KATP 
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channels since both A2AAR- and A2BAR-meditaed CF effects were abolished in the 
presence of glibenclamide (Figure 3.7).   
Whereas we showed that activation of both A2AARs and A2BARs induces CF 
vasodilation, in this dissertation we established that only A2AARs contribute to the 
regulation of CF in reactive hyperemia, where the metabolic factors are known to be 
mainly involved. It is interesting to mention that A2AARs induce the sustained coronary 
vasodilation during reactive hyperemia through the release of H2O2. H2O2, depending on 
the vascular bed and its concentration, acts as a vasorelaxing as well as a vasoconstricting 
factor. Using isolated mouse hearts, we showed that exogenous H2O2 may have a tissue-
protective role by inducing coronary vasodilation. In addition, we established that H2O2, 
released due to activation of A2AARs, also activates KATP channels on smooth muscle 
cells, which further confirms our findings that KATP channels may be the end effector in 
A2AR-mediated effect on CF (Figure 5.1).  
The availability of single and double knockout ARs is a valuable tool to better 
understand the role of each AR or a subclass of AR subtype. In addition to measurement 
of baseline parameters, such as baseline CF, heart rate, and left ventricle developed 
pressure, we also showed that the recently available A2BKO mice have a functional 
endothelium by showing that bradykinin response was not different in A2BKO mice 
compared with wild type mice.  
In summary, both A2A and A2B ARs are capable of inducing coronary 
vasodilation, but they each are activated endogenously under different conditions. 
Needless to say, the role of A2ARs in the regulation of CF is much more complicated 
than what has been described in this thesis.  It is possible that there might also be other 
interactions present between this class of GPCRs and β adrenoceptors, in view of the fact 
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that NECA-mediated increase in CF is ameliorated in β1/β2 double knockout mice 
(Appendix A). These findings require more detailed investigation to better understand the 























































The next step for this project would be to identify the source of H2O2; H2O2 may 
be released from the myocardium or the vascular bed itself, in which case, the knowledge 
of whether the source is the endothelium or SMCs may help us to identify the mechanism 
behind reduced adenosine coronary response in patients with cardiovascular disease. 
Furthermore, it would be interesting to identify the factor(s) responsible for the release of 
superoxide, which subsequently leads to the formation of H2O2; among the possible 
factors, NADPH oxidases and mitochondria are the primary candidate sources of 
superoxides (Figure 5.2).  
The NADPH oxidase-enzyme complex consists of two membrane-bound 
components (gp91phox [also known as NADPH oxidase (Nox)-2] and p22phox) and 
several cytosolic regulatory subunits, including p47phox, p67phox, and the small GTPase 
Rac (Rac1 or Rac2). When NADPH oxidase becomes activated, the cytoplasmic subunits 
translocate to the cell membrane and the resulting complex transfers electrons from 
NADPH to molecular oxygen in order to form superoxide. In fact, NADPH oxidase is 
identified as a major source of superoxide in ECs, and, therefore, the important 
determinants of the oxidation-reduction (redox) state of the endothelium. Investigators 
have also identified NADPH oxidase complex as the major source of ROS in VSMCs. 
Whereas both p22phox and p47phox appear to be essential for NADPH oxidase activity 
in VSMCs, targeted-deletion of the gp91phox gene in mice had no effect on superoxide 
production (3). Additionally, two homologues of gp91phox, termed Nox1 and Nox4, are 
suggested to be mainly present on vascular beds. Therefore, the association of the 
NADPH oxidase homologue involved in adenosine-mediated release of H2O2, and hence 
coronary vasodilation, needs to be clarified.  
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In many cells, the majority of superoxide is generated from mitochondria via 
cellular respiration and specifically during ubisemiquinone autoxidation. Ubisemiquinone 
can serve as an electron donor to O2 to produce superoxide. Electron flow through the 
mitochondrial electron transfer chain occurs by four inner membrane–associated enzyme 
complexes, with cytochrome c and the mobile carrier ubiquinone. NADH derived from 
both cytosol and mitochondria donate electrons to NADH:ubiquinone oxidoreductase 
(complex I) which then transfers its electrons to succinate:ubiquinone oxidoreductase 
(complex II). Electrons from reduced ubiquinone are then transferred to 
ubiquinol:cytochrome c oxidoreductase (complex III). Electron transport then proceeds 
through cytochrome c, cytochrome c oxidase (complex IV), and finally, molecular 
oxygen (5-6). Nevertheless, there are two major mitochondrial electron transfer chain 
regions where ROS are produced: complex I and complex III. Therefore, in order to 
identify the mitochondrial complex involved in H2O2 production, we can use rotenone, a 
complex I inhibitor, myxothiazol, which inhibits oxidation of ubiquinol to 
ubisemiquinone in complex III, and cyanide, a complex IV inhibitor, to detect if the 
trapped radical species originates from the electron transport chain of the mitochondria. 
Cardioprotective effect of carvedilol (βADR blocker) was shown to be through an 
adenosine-dependent mechanism. Additionally, it was reported that βADR-mediated 
inotropic responses were attenuated by adenosine (7). Our preliminary data also 
establishes a relationship between βADRs and A2ARs since the effect of NECA is 
attenuated in β1/β2DKO mice. Therefore, a better understanding of the relationship 
between ARs and βADRs in CF regulation and the possible signaling pathways involved, 
would open a new window to better understand the heterogeneity CF regulation in 
relation to ARs. Our preliminary data show that, like any complex system, regulation of 
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CF may further involve an interaction between ARs and βADRs. Nevertheless, this 
investigation requires further experiments to confirm the presence of such a relationship 
between these two classes of GPCRs.  
Finally, our data show that A2BARs are not involved in RH and may play a role in 
severe ischemic conditions, where adenosine levels are significantly higher. Therefore, in 
order to better clarify the role of A2BARs in CF regulation, further experiments such as 
ischemia/reperfusion experiments are needed. Indeed, is has been reported that A2BARs 
play a cardioprotective role during ischemia/reperfusion (1-2, 4). Therefore, taken 
together, elucidation of CF regulation and cardioprotection in light of A2BARs and 
βADRs, and, ultimately, understanding the signaling pathways involved, would lead to 
uncovering of the translational mechanisms of cardiac reperfusion subsequent to a heart 
attack, in addition to finding of better and complete ways of cardiac imaging evaluation 
for the diagnosis of coronary artery disease (Figure 5.2).     





Figure 5.2 Future directions for identifications of A2AARs and A2BARs signaling 
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                                                            APPENDIX A 
 
Preliminary experiments (relationship between adenosine receptors and β1 and β2 
adrenoceptors) were carried out. The concentration-response curve for NECA was 
calculated in WT (FVB) and β2KO mice isolated hearts. This was done to determine 
the role of A2ARs in NECA-induced relaxation in β2KO. There was no difference 
between the two groups. 
 



































































































Preliminary experiments (relationship between adenosine receptors and β1 and β2 
adrenoceptors) were carried out. The concentration-response curve for NECA was 
calculated in WT (FVB), WT (C57), and β1/2DKO mice isolated hearts. This was 
done to determine the role of A2ARs in NECA-induced relaxation in β1/2DKO. There 
was no difference between the two control groups while NECA-mediated effects 
were significantly diminished in β1/2DKO compared to both controls. 








































































































Preliminary experiments (relationship between adenosine receptors and β1 and β2 
adrenoceptors) were carried out. The concentration-response curve for CCPA was 
calculated in WT (FVB) and β1/2DKO mice isolated hearts. This was done to 
determine the role of A1AR-mediated effect in β1/2DKO. There was no difference 
between the two groups. 
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